US20210403460A1 - Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof - Google Patents
Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof Download PDFInfo
- Publication number
- US20210403460A1 US20210403460A1 US17/472,646 US202117472646A US2021403460A1 US 20210403460 A1 US20210403460 A1 US 20210403460A1 US 202117472646 A US202117472646 A US 202117472646A US 2021403460 A1 US2021403460 A1 US 2021403460A1
- Authority
- US
- United States
- Prior art keywords
- mmol
- amino
- pyrimidin
- ethyl
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title description 126
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 title description 8
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 title description 8
- 239000003112 inhibitor Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 103
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 70
- 201000010099 disease Diseases 0.000 claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 208000035475 disorder Diseases 0.000 claims abstract description 26
- 125000003118 aryl group Chemical group 0.000 claims description 53
- 125000003545 alkoxy group Chemical group 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 22
- 239000003085 diluting agent Substances 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 239000003937 drug carrier Substances 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 18
- 150000003973 alkyl amines Chemical class 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- 125000000524 functional group Chemical group 0.000 claims description 15
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 230000002489 hematologic effect Effects 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims description 4
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 237
- 239000000243 solution Substances 0.000 description 174
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 120
- 238000010898 silica gel chromatography Methods 0.000 description 117
- 235000019439 ethyl acetate Nutrition 0.000 description 115
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 112
- 239000012044 organic layer Substances 0.000 description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 104
- 239000007787 solid Substances 0.000 description 98
- 239000007832 Na2SO4 Substances 0.000 description 87
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 87
- 229910052938 sodium sulfate Inorganic materials 0.000 description 87
- -1 enol esters Chemical class 0.000 description 69
- 239000011541 reaction mixture Substances 0.000 description 62
- 239000012267 brine Substances 0.000 description 51
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 51
- SGFTXOWTCSRALD-MRVPVSSYSA-N (4S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound ClC=1N=C(C2=C(N=1)C=CS2)N1C(OC[C@@H]1C(C)C)=O SGFTXOWTCSRALD-MRVPVSSYSA-N 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 47
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- WZPLIWXJPQREDV-HRAATJIYSA-N (4S)-3-[2-[[(1S)-1-[4-(piperidin-4-ylamino)phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)NC1CCNCC1)C=CS2 WZPLIWXJPQREDV-HRAATJIYSA-N 0.000 description 42
- YULRBPIQXHRQJI-MGPUTAFESA-N (4S)-3-[2-[[(1S)-1-[4-[(5-nitropyridin-2-yl)amino]phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)NC1=NC=C(C=C1)[N+](=O)[O-])C=CS2 YULRBPIQXHRQJI-MGPUTAFESA-N 0.000 description 39
- KZVGNBKQAFADGE-LBPRGKRZSA-N tert-butyl N-[(1S)-1-[4-[(5-nitropyridin-2-yl)amino]phenyl]ethyl]carbamate Chemical compound [N+](=O)([O-])C=1C=CC(=NC=1)NC1=CC=C(C=C1)[C@H](C)NC(OC(C)(C)C)=O KZVGNBKQAFADGE-LBPRGKRZSA-N 0.000 description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- HJBXQHVPOAPTQO-BLLLJJGKSA-N (4S)-3-[2-[[(1S)-1-(4-bromophenyl)ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound BrC1=CC=C(C=C1)[C@H](C)NC=1N=C(C2=C(N=1)C=CS2)N1C(OC[C@@H]1C(C)C)=O HJBXQHVPOAPTQO-BLLLJJGKSA-N 0.000 description 33
- 125000001072 heteroaryl group Chemical group 0.000 description 32
- 0 **C1=C(*B)C(N2C(=O)OC[C@@H]2C(C)C)=NC(NC(C)C)=N1 Chemical compound **C1=C(*B)C(N2C(=O)OC[C@@H]2C(C)C)=NC(NC(C)C)=N1 0.000 description 30
- ANWIRDPJKFPWBF-MGPUTAFESA-N (4S)-3-[2-[[(1S)-1-[4-[(5-aminopyridin-2-yl)amino]phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC=1C=CC(=NC=1)NC1=CC=C(C=C1)[C@H](C)NC=1N=C(C2=C(N=1)C=CS2)N1C(OC[C@@H]1C(C)C)=O ANWIRDPJKFPWBF-MGPUTAFESA-N 0.000 description 28
- 125000000217 alkyl group Chemical group 0.000 description 28
- AEFGTULIXZKQJP-YADARESESA-N tert-butyl 4-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]anilino]piperidine-1-carboxylate Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)NC1CCN(CC1)C(=O)OC(C)(C)C)C=CS2 AEFGTULIXZKQJP-YADARESESA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 27
- FDRRZUGAMUVYJE-LAUBAEHRSA-N (4S)-3-[2-[[(1S)-1-[4-(piperazin-1-ylmethyl)phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)CN1CCNCC1)C=CS2 FDRRZUGAMUVYJE-LAUBAEHRSA-N 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- CMYCIRFZJKISNU-SSDOTTSWSA-N (4s)-3-(2-chloropyrimidin-4-yl)-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)[C@H]1COC(=O)N1C1=CC=NC(Cl)=N1 CMYCIRFZJKISNU-SSDOTTSWSA-N 0.000 description 23
- RFPYZFLYHZRKIG-NEKDWFFYSA-N benzyl 4-[[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]phenyl]methyl]piperazine-1-carboxylate Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(CN3CCN(CC3)C(=O)OCC3=CC=CC=C3)C=C1)C=CS2 RFPYZFLYHZRKIG-NEKDWFFYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 150000003839 salts Chemical class 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 21
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- 125000005842 heteroatom Chemical group 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 239000008346 aqueous phase Substances 0.000 description 17
- 239000001257 hydrogen Substances 0.000 description 17
- XSYGLHLLQZGWPT-ZETCQYMHSA-N methyl 4-[(1s)-1-aminoethyl]benzoate Chemical compound COC(=O)C1=CC=C([C@H](C)N)C=C1 XSYGLHLLQZGWPT-ZETCQYMHSA-N 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 239000000651 prodrug Substances 0.000 description 17
- 229940002612 prodrug Drugs 0.000 description 17
- 125000006413 ring segment Chemical group 0.000 description 17
- 238000000926 separation method Methods 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 15
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 13
- 125000003710 aryl alkyl group Chemical group 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 125000001188 haloalkyl group Chemical group 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 11
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 125000004452 carbocyclyl group Chemical group 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- YWJMIZZYUADCCJ-VIFPVBQESA-O tert-butyl N-[(1S)-1-(4-bromophenyl)ethyl]carbamate Chemical compound BrC1=CC=C(C=C1)[C@H]([CH2+])NC(=O)OC(C)(C)C YWJMIZZYUADCCJ-VIFPVBQESA-O 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- YBUPWRYTXGAWJX-RXMQYKEDSA-N (4s)-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)[C@H]1COC(=O)N1 YBUPWRYTXGAWJX-RXMQYKEDSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- RXMRCMRYQXEJLO-KRWDZBQOSA-N benzyl 4-[[4-[(1s)-1-aminoethyl]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1=CC([C@@H](N)C)=CC=C1CN1CCN(C(=O)OCC=2C=CC=CC=2)CC1 RXMRCMRYQXEJLO-KRWDZBQOSA-N 0.000 description 9
- LFNXGVQOIUBOOG-JTQLQIEISA-N methyl 4-[(1s)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]benzoate Chemical compound COC(=O)C1=CC=C([C@H](C)NC(=O)OC(C)(C)C)C=C1 LFNXGVQOIUBOOG-JTQLQIEISA-N 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 125000000168 pyrrolyl group Chemical group 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- SVLPTAAWQOWODK-ZMVRRDJGSA-N C=CC(=O)C(C)(C)C.C=CC(=O)NC(C)(C)C.CCC(=O)NC(C)(C)C.CN(C)C/C=C/C(=O)NC(C)(C)C Chemical compound C=CC(=O)C(C)(C)C.C=CC(=O)NC(C)(C)C.CCC(=O)NC(C)(C)C.CN(C)C/C=C/C(=O)NC(C)(C)C SVLPTAAWQOWODK-ZMVRRDJGSA-N 0.000 description 8
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 8
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- LKDZRILUEICRLT-FQEVSTJZSA-N benzyl 4-[[4-[(1s)-1-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]phenyl]methyl]piperazine-1-carboxylate Chemical compound C1=CC([C@@H](NC(=O)OC(C)(C)C)C)=CC=C1CN1CCN(C(=O)OCC=2C=CC=CC=2)CC1 LKDZRILUEICRLT-FQEVSTJZSA-N 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- 239000012047 saturated solution Substances 0.000 description 8
- 239000011593 sulfur Substances 0.000 description 8
- WNIOYQBDDWKYPN-JTQLQIEISA-N tert-butyl n-[(1s)-1-[4-(chloromethyl)phenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C1=CC=C(CCl)C=C1 WNIOYQBDDWKYPN-JTQLQIEISA-N 0.000 description 8
- IKDSQAZPZFBIIK-JTQLQIEISA-N tert-butyl n-[(1s)-1-[4-(hydroxymethyl)phenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C1=CC=C(CO)C=C1 IKDSQAZPZFBIIK-JTQLQIEISA-N 0.000 description 8
- XQYMOEFQAQPZFV-FXAWDEMLSA-N (4s)-3-[2-[[(1s)-1-[4-(piperazin-1-ylmethyl)phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)[C@H]1COC(=O)N1C1=CC=NC(N[C@@H](C)C=2C=CC(CN3CCNCC3)=CC=2)=N1 XQYMOEFQAQPZFV-FXAWDEMLSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 125000002393 azetidinyl group Chemical group 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 125000004193 piperazinyl group Chemical group 0.000 description 7
- 125000003386 piperidinyl group Chemical group 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- SOZMSEPDYJGBEK-LURJTMIESA-N (1s)-1-(4-bromophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(Br)C=C1 SOZMSEPDYJGBEK-LURJTMIESA-N 0.000 description 6
- BRAJWDFOPWRMNH-XCWJXAQQSA-N (4S)-3-[2-[1-[5-(4-amino-N-methylanilino)pyrimidin-2-yl]ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC1=CC=C(C=C1)N(C=1C=NC(=NC=1)C(C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O)C BRAJWDFOPWRMNH-XCWJXAQQSA-N 0.000 description 6
- YTCAZZRETOGVCD-HRAATJIYSA-N (4S)-3-[2-[[(1S)-1-[4-(4-aminoanilino)phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC1=CC=C(C=C1)NC1=CC=C(C=C1)[C@H](C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O YTCAZZRETOGVCD-HRAATJIYSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- ZUZVRVFAUSSLNI-UHFFFAOYSA-N 1-(5-bromopyrimidin-2-yl)ethanamine Chemical compound CC(N)C1=NC=C(Br)C=N1 ZUZVRVFAUSSLNI-UHFFFAOYSA-N 0.000 description 6
- XTAKQONFXDJSHA-UHFFFAOYSA-N 1-(5-bromopyrimidin-2-yl)ethanol Chemical compound CC(O)C1=NC=C(Br)C=N1 XTAKQONFXDJSHA-UHFFFAOYSA-N 0.000 description 6
- FVMUWUXJMLJEIE-UHFFFAOYSA-N 2-(1-azidoethyl)-5-bromopyrimidine Chemical compound N(=[N+]=[N-])C(C)C1=NC=C(C=N1)Br FVMUWUXJMLJEIE-UHFFFAOYSA-N 0.000 description 6
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 6
- LYOVHEPTNRIWCK-JTQLQIEISA-N 4-[(1S)-1-aminoethyl]-N-(4-nitrophenyl)aniline Chemical compound N[C@@H](C)C1=CC=C(NC2=CC=C(C=C2)[N+](=O)[O-])C=C1 LYOVHEPTNRIWCK-JTQLQIEISA-N 0.000 description 6
- VQAUKMGPGPXKPH-VIFPVBQESA-N N-[4-[(1S)-1-aminoethyl]phenyl]-5-nitropyridin-2-amine Chemical compound N[C@@H](C)C1=CC=C(C=C1)NC1=NC=C(C=C1)[N+](=O)[O-] VQAUKMGPGPXKPH-VIFPVBQESA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 102200069708 rs121913499 Human genes 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- IPNLCMNTVDRQNP-UHFFFAOYSA-N tert-butyl n-[1-(5-bromopyrimidin-2-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C)C1=NC=C(Br)C=N1 IPNLCMNTVDRQNP-UHFFFAOYSA-N 0.000 description 6
- TVPVAGUBJCNUSJ-UHFFFAOYSA-N 1,1-diazidoguanidine Chemical group [N-]=[N+]=NN(C(=N)N)N=[N+]=[N-] TVPVAGUBJCNUSJ-UHFFFAOYSA-N 0.000 description 5
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical group [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 101001042415 Cratylia mollis Mannose/glucose-specific lectin Cramoll Proteins 0.000 description 5
- 101001012787 Homo sapiens Eukaryotic translation initiation factor 1 Proteins 0.000 description 5
- 101000643378 Homo sapiens Serine racemase Proteins 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 102100035717 Serine racemase Human genes 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- DVDWCHHLKXYBCX-WNCULLNHSA-N benzyl 4-[[4-[(1s)-1-[[4-[(4s)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]phenyl]methyl]piperazine-1-carboxylate Chemical compound CC(C)[C@H]1COC(=O)N1C1=CC=NC(N[C@@H](C)C=2C=CC(CN3CCN(CC3)C(=O)OCC=3C=CC=CC=3)=CC=2)=N1 DVDWCHHLKXYBCX-WNCULLNHSA-N 0.000 description 5
- 239000004202 carbamide Chemical group 0.000 description 5
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- AIXMJTYHQHQJLU-UHFFFAOYSA-N chembl210858 Chemical compound O1C(CC(=O)OC)CC(C=2C=CC(O)=CC=2)=N1 AIXMJTYHQHQJLU-UHFFFAOYSA-N 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 5
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 5
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- 125000005864 sulfonamidyl group Chemical group 0.000 description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 125000004962 sulfoxyl group Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XWAXDRXXNYJVQU-ZDUSSCGKSA-N tert-butyl N-[(1S)-1-[4-(4-nitroanilino)phenyl]ethyl]carbamate Chemical compound [N+](=O)([O-])C1=CC=C(C=C1)NC1=CC=C(C=C1)[C@H](C)NC(OC(C)(C)C)=O XWAXDRXXNYJVQU-ZDUSSCGKSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- AQECFYPZMBRCIA-UHFFFAOYSA-N 2,4-dichlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2SC=CC2=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 101000599885 Dictyostelium discoideum Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910001873 dinitrogen Inorganic materials 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000002427 irreversible effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- PWLDNGOSBDHNAE-XPKAQORNSA-N (4S)-3-[2-[1-[5-(3-aminophenyl)pyrimidin-2-yl]ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC=1C=C(C=CC=1)C=1C=NC(=NC=1)C(C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O PWLDNGOSBDHNAE-XPKAQORNSA-N 0.000 description 3
- GEPCFJKXVSCBQC-XCWJXAQQSA-N (4S)-3-[2-[1-[5-(N-methyl-4-nitroanilino)pyrimidin-2-yl]ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C1=NC=C(C=N1)N(C1=CC=C(C=C1)[N+](=O)[O-])C GEPCFJKXVSCBQC-XCWJXAQQSA-N 0.000 description 3
- GPIOOUWOTCLOAF-KSFYIVLOSA-N (4S)-3-[2-[[(1S)-1-[4-(4-aminoanilino)phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC1=CC=C(C=C1)NC1=CC=C(C=C1)[C@H](C)NC=1N=C(C2=C(N=1)C=CS2)N1C(OC[C@@H]1C(C)C)=O GPIOOUWOTCLOAF-KSFYIVLOSA-N 0.000 description 3
- KWDOBDNPTHMYBH-HRAATJIYSA-N (4S)-3-[2-[[(1S)-1-[4-(4-nitroanilino)phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C1=CC=C(C=C1)NC1=CC=C(C=C1)[N+](=O)[O-] KWDOBDNPTHMYBH-HRAATJIYSA-N 0.000 description 3
- NKJZELHWGLSGFP-SWLSCSKDSA-N (4s)-3-[2-[[(1s)-1-(4-bromophenyl)ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)[C@H]1COC(=O)N1C1=CC=NC(N[C@@H](C)C=2C=CC(Br)=CC=2)=N1 NKJZELHWGLSGFP-SWLSCSKDSA-N 0.000 description 3
- KVUBBIXDVHOQLB-UHFFFAOYSA-N 1-(2-piperidin-4-yloxypyrimidin-5-yl)ethanone Chemical compound CC(=O)C1=CN=C(OC2CCNCC2)N=C1 KVUBBIXDVHOQLB-UHFFFAOYSA-N 0.000 description 3
- MQGHBPGBHHSHSU-UHFFFAOYSA-N 1-[5-(3-nitrophenyl)pyrimidin-2-yl]ethanamine Chemical compound CC(N)C1=NC=C(C=N1)C1=CC(=CC=C1)[N+]([O-])=O MQGHBPGBHHSHSU-UHFFFAOYSA-N 0.000 description 3
- ILWKSPBAWYKLQH-UHFFFAOYSA-N 2-(1-aminoethyl)-N-methyl-N-(4-nitrophenyl)pyrimidin-5-amine Chemical compound NC(C)C1=NC=C(C=N1)N(C1=CC=C(C=C1)[N+](=O)[O-])C ILWKSPBAWYKLQH-UHFFFAOYSA-N 0.000 description 3
- BMXJFKLSEGBBSJ-UHFFFAOYSA-N 5-bromo-2-(bromomethyl)pyrimidine Chemical compound BrCC1=NC=C(Br)C=N1 BMXJFKLSEGBBSJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- DFUQNPVCESXFGG-MNSRQFJYSA-N CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.ClC1=NC(Cl)=NC=C1 Chemical compound CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.ClC1=NC(Cl)=NC=C1 DFUQNPVCESXFGG-MNSRQFJYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 229910020889 NaBH3 Inorganic materials 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- AFGUOAYKLDWTAX-UHFFFAOYSA-N benzyl 4-[(5-acetylpyrimidin-2-yl)methyl]piperazine-1-carboxylate Chemical compound C(C)(=O)C=1C=NC(=NC=1)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1 AFGUOAYKLDWTAX-UHFFFAOYSA-N 0.000 description 3
- LVQUSYAGLNBSJE-UHFFFAOYSA-N benzyl 4-[(5-bromopyrimidin-2-yl)methyl]piperazine-1-carboxylate Chemical compound BrC=1C=NC(=NC=1)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1 LVQUSYAGLNBSJE-UHFFFAOYSA-N 0.000 description 3
- YKRCNLMRVQGKPD-UHFFFAOYSA-N benzyl 4-[[5-(1-aminoethyl)pyrimidin-2-yl]methyl]piperazine-1-carboxylate Chemical compound NC(C)C=1C=NC(=NC=1)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1 YKRCNLMRVQGKPD-UHFFFAOYSA-N 0.000 description 3
- UZLDGDKREXPOAS-MQNHUJCZSA-N benzyl 4-[[5-[1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]pyrimidin-2-yl]methyl]piperazine-1-carboxylate Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C=1C=NC(=NC=1)CN1CCN(CC1)C(=O)OCC1=CC=CC=C1 UZLDGDKREXPOAS-MQNHUJCZSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229940068917 polyethylene glycols Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RZDDOCFEAHFXDV-UHFFFAOYSA-N tert-butyl 4-(5-acetylpyridin-2-yl)oxypiperidine-1-carboxylate Chemical compound N1=CC(C(=O)C)=CC=C1OC1CCN(C(=O)OC(C)(C)C)CC1 RZDDOCFEAHFXDV-UHFFFAOYSA-N 0.000 description 3
- ZSFWXQRQUWUXBY-UHFFFAOYSA-N tert-butyl 4-(5-acetylpyrimidin-2-yl)oxypiperidine-1-carboxylate Chemical compound C(C)(=O)C=1C=NC(=NC=1)OC1CCN(CC1)C(=O)OC(C)(C)C ZSFWXQRQUWUXBY-UHFFFAOYSA-N 0.000 description 3
- LATUROZPOJVDKS-UHFFFAOYSA-N tert-butyl 4-(5-bromopyrimidin-2-yl)oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=C(Br)C=N1 LATUROZPOJVDKS-UHFFFAOYSA-N 0.000 description 3
- DTYVADXCEBGVFA-UUSAFJCLSA-N tert-butyl 4-[5-[1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]pyrimidin-2-yl]oxypiperidine-1-carboxylate Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C=1C=NC(=NC=1)OC1CCN(CC1)C(=O)OC(C)(C)C DTYVADXCEBGVFA-UUSAFJCLSA-N 0.000 description 3
- YSWZIRDPWNZOMN-UHFFFAOYSA-N tert-butyl N-[1-[5-(N-methyl-4-nitroanilino)pyrimidin-2-yl]ethyl]carbamate Chemical compound CN(C=1C=NC(=NC=1)C(C)NC(OC(C)(C)C)=O)C1=CC=C(C=C1)[N+](=O)[O-] YSWZIRDPWNZOMN-UHFFFAOYSA-N 0.000 description 3
- GGKUZHMCYJPNNC-YADARESESA-N tert-butyl N-[3-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]anilino]phenyl]carbamate Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C1=CC=C(C=C1)NC=1C=C(C=CC=1)NC(OC(C)(C)C)=O GGKUZHMCYJPNNC-YADARESESA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- UDSUZJQPWRRRTD-NSHDSACASA-N (3S)-1-[(4-nitrophenyl)methyl]piperidin-3-amine Chemical compound [N+](=O)([O-])C1=CC=C(CN2C[C@H](CCC2)N)C=C1 UDSUZJQPWRRRTD-NSHDSACASA-N 0.000 description 2
- NWKNPUOJTXNKHP-FBMWCMRBSA-N (4S)-3-[2-[1-(2-piperidin-4-yloxypyrimidin-5-yl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C=1C=NC(=NC=1)OC1CCNCC1 NWKNPUOJTXNKHP-FBMWCMRBSA-N 0.000 description 2
- ZZDVSKCYVQHQAH-KPMSDPLLSA-N (4S)-3-[2-[1-(6-piperidin-4-yloxypyridin-3-yl)ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C=1C=NC(=CC=1)OC1CCNCC1 ZZDVSKCYVQHQAH-KPMSDPLLSA-N 0.000 description 2
- HGNSXCJLAVVKNT-OMOCHNIRSA-N (4S)-3-[2-[1-[2-(piperazin-1-ylmethyl)pyrimidin-5-yl]ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C=1C=NC(=NC=1)CN1CCNCC1 HGNSXCJLAVVKNT-OMOCHNIRSA-N 0.000 description 2
- YCJLLXVBDIKODB-XPKAQORNSA-N (4S)-3-[2-[1-[5-(3-nitrophenyl)pyrimidin-2-yl]ethylamino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C1=NC=C(C=N1)C1=CC(=CC=C1)[N+](=O)[O-] YCJLLXVBDIKODB-XPKAQORNSA-N 0.000 description 2
- LHKVROAGESFIMV-KSFYIVLOSA-N (4S)-3-[2-[[(1S)-1-[4-(4-nitroanilino)phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)NC1=CC=C(C=C1)[N+](=O)[O-])C=CS2 LHKVROAGESFIMV-KSFYIVLOSA-N 0.000 description 2
- RQZBIVMPCAEJFQ-HNAYVOBHSA-N (4S)-3-[2-[[(1S)-1-[4-[(5-aminopyridin-2-yl)amino]phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC=1C=CC(=NC=1)NC1=CC=C(C=C1)[C@H](C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O RQZBIVMPCAEJFQ-HNAYVOBHSA-N 0.000 description 2
- SGGOTPBHJAWRFT-HNAYVOBHSA-N (4S)-3-[2-[[(1S)-1-[4-[(5-nitropyridin-2-yl)amino]phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C1=CC=C(C=C1)NC1=NC=C(C=C1)[N+](=O)[O-] SGGOTPBHJAWRFT-HNAYVOBHSA-N 0.000 description 2
- IVEREOXQQMRHGW-MSQFKCCISA-N (4S)-3-[2-[[(1S)-1-[4-[[4-[(E)-4-(dimethylamino)but-2-enoyl]piperazin-1-yl]methyl]phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CN(C/C=C/C(=O)N1CCN(CC1)CC1=CC=C(C=C1)[C@H](C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O)C IVEREOXQQMRHGW-MSQFKCCISA-N 0.000 description 2
- OXGTXKVQTYFGOV-RBUKOAKNSA-N (4S)-3-[2-[[(3S)-1-[(4-aminophenyl)methyl]piperidin-3-yl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC1=CC=C(CN2C[C@H](CCC2)NC2=NC=CC(=N2)N2C(OC[C@@H]2C(C)C)=O)C=C1 OXGTXKVQTYFGOV-RBUKOAKNSA-N 0.000 description 2
- WQOCGCMZDGPTOV-PKOBYXMFSA-N (4S)-3-[2-[[(3S)-1-[(4-nitrophenyl)methyl]piperidin-3-yl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H]1CN(CCC1)CC1=CC=C(C=C1)[N+](=O)[O-] WQOCGCMZDGPTOV-PKOBYXMFSA-N 0.000 description 2
- ZJFAQWLZBDMGFF-LJQANCHMSA-N (4S)-3-[2-[[1-[(4-aminophenyl)methyl]piperidin-4-yl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC1=CC=C(CN2CCC(CC2)NC2=NC=CC(=N2)N2C(OC[C@@H]2C(C)C)=O)C=C1 ZJFAQWLZBDMGFF-LJQANCHMSA-N 0.000 description 2
- WEMOLYIWDVTDMU-LJQANCHMSA-N (4S)-3-[2-[[1-[(4-nitrophenyl)methyl]piperidin-4-yl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC1CCN(CC1)CC1=CC=C(C=C1)[N+](=O)[O-] WEMOLYIWDVTDMU-LJQANCHMSA-N 0.000 description 2
- LMUYZTICKCSLLU-UHUGOGIASA-N (4S)-3-[2-[[1-[(4-nitrophenyl)methyl]pyrrolidin-3-yl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC1CN(CC1)CC1=CC=C(C=C1)[N+](=O)[O-] LMUYZTICKCSLLU-UHUGOGIASA-N 0.000 description 2
- ZFKKRAUMVZAEEW-LRTDYKAYSA-N (4S)-4-propan-2-yl-3-[2-[1-[2-(1-prop-2-enoylpiperidin-4-yl)oxypyrimidin-5-yl]ethylamino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C(C=C)(=O)N1CCC(CC1)OC1=NC=C(C=N1)C(C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O ZFKKRAUMVZAEEW-LRTDYKAYSA-N 0.000 description 2
- QQJUTDAVLMGTEM-WHCXFUJUSA-N (4S)-4-propan-2-yl-3-[2-[1-[2-[(4-prop-2-enoylpiperazin-1-yl)methyl]pyrimidin-5-yl]ethylamino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C(C=C)(=O)N1CCN(CC1)CC1=NC=C(C=N1)C(C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O QQJUTDAVLMGTEM-WHCXFUJUSA-N 0.000 description 2
- WABGYDOAKZUOQM-UUSAFJCLSA-N (4S)-4-propan-2-yl-3-[2-[1-[6-(1-prop-2-enoylpiperidin-4-yl)oxypyridin-3-yl]ethylamino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C(C=C)(=O)N1CCC(CC1)OC1=CC=C(C=N1)C(C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O WABGYDOAKZUOQM-UUSAFJCLSA-N 0.000 description 2
- YRPDSXWBNDZCQO-FDDCHVKYSA-N (4S)-4-propan-2-yl-3-[2-[[(1S)-1-[4-[(1-prop-2-enoylpiperidin-4-yl)amino]phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C(C=C)(=O)N1CCC(CC1)NC1=CC=C(C=C1)[C@H](C)NC=1N=C(C2=C(N=1)C=CS2)N1C(OC[C@@H]1C(C)C)=O YRPDSXWBNDZCQO-FDDCHVKYSA-N 0.000 description 2
- QJOKNPGINIBOJX-SIKLNZKXSA-N (4S)-4-propan-2-yl-3-[2-[[(1S)-1-[4-[(4-prop-2-enoylpiperazin-1-yl)methyl]phenyl]ethyl]amino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C(C=C)(=O)N1CCN(CC1)CC1=CC=C(C=C1)[C@H](C)NC1=NC=CC(=N1)N1C(OC[C@@H]1C(C)C)=O QJOKNPGINIBOJX-SIKLNZKXSA-N 0.000 description 2
- AGPSLMIIPOGVRV-WMZHIEFXSA-N (4S)-4-propan-2-yl-3-[2-[[(1S)-1-[4-[(4-prop-2-enoylpiperazin-1-yl)methyl]phenyl]ethyl]amino]thieno[3,2-d]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C(C=C)(=O)N1CCN(CC1)CC1=CC=C(C=C1)[C@H](C)NC=1N=C(C2=C(N=1)C=CS2)N1C(OC[C@@H]1C(C)C)=O AGPSLMIIPOGVRV-WMZHIEFXSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000005869 (methoxyethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 125000005867 (methoxymethoxy)ethanyl group Chemical group [H]C([H])([H])OC([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000005868 (methoxymethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])OC([H])([H])* 0.000 description 2
- UXSNZYGTQTXRAD-UHFFFAOYSA-N 1-(6-chloropyridin-3-yl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)N=C1 UXSNZYGTQTXRAD-UHFFFAOYSA-N 0.000 description 2
- UHIQIZHKFBGXFN-UHFFFAOYSA-N 1-[(4-nitrophenyl)methyl]piperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=C([N+]([O-])=O)C=C1 UHIQIZHKFBGXFN-UHFFFAOYSA-N 0.000 description 2
- QSZRYYRJYVORIT-UHFFFAOYSA-N 1-[(4-nitrophenyl)methyl]pyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1=CC=C([N+]([O-])=O)C=C1 QSZRYYRJYVORIT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 2
- ZEZKXPQIDURFKA-UHFFFAOYSA-N 5-bromo-2-iodopyrimidine Chemical compound BrC1=CN=C(I)N=C1 ZEZKXPQIDURFKA-UHFFFAOYSA-N 0.000 description 2
- UGSBCCAHDVCHGI-UHFFFAOYSA-N 5-nitropyridin-2-amine Chemical compound NC1=CC=C([N+]([O-])=O)C=N1 UGSBCCAHDVCHGI-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical group NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IABYEJXISTXNRB-FEHMZFNZSA-M C1CCOC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCCCC3)C=C2)=NC=C1.COC(=O)C1=CC=C([C@H](C)N)C=C1.COC(=O)C1=CC=C([C@H](C)NC(=O)OC(C)(C)C)C=C1.CS(=O)(=O)Cl.C[C@H](N)C1=CC=C(CC2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CC2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CCl)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CO)C=C1.O=C(OCC1=CC=CC=C1)N1CCNCC1.O=COO[K].[AlH3].[KH].[LiH] Chemical compound C1CCOC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCCCC3)C=C2)=NC=C1.COC(=O)C1=CC=C([C@H](C)N)C=C1.COC(=O)C1=CC=C([C@H](C)NC(=O)OC(C)(C)C)C=C1.CS(=O)(=O)Cl.C[C@H](N)C1=CC=C(CC2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CC2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CCl)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CO)C=C1.O=C(OCC1=CC=CC=C1)N1CCNCC1.O=COO[K].[AlH3].[KH].[LiH] IABYEJXISTXNRB-FEHMZFNZSA-M 0.000 description 2
- YVSFORYUCHLMKP-ZMVRRDJGSA-N C=CC(=O)C(C)(C)C.C=CC(=O)NC(C)(C)C.CC(C)(C)NC(=O)CCl.CN(C)C/C=C/C(=O)NC(C)(C)C Chemical compound C=CC(=O)C(C)(C)C.C=CC(=O)NC(C)(C)C.CC(C)(C)NC(=O)CCl.CN(C)C/C=C/C(=O)NC(C)(C)C YVSFORYUCHLMKP-ZMVRRDJGSA-N 0.000 description 2
- QYQIYDLDKLRBIE-VOTSOKGWSA-N CC(C)(C)NC(/C=C/CN(C)C)=O Chemical compound CC(C)(C)NC(/C=C/CN(C)C)=O QYQIYDLDKLRBIE-VOTSOKGWSA-N 0.000 description 2
- XFHJDMUEHUHAJW-UHFFFAOYSA-N CC(C)(C)NC(C=C)=O Chemical compound CC(C)(C)NC(C=C)=O XFHJDMUEHUHAJW-UHFFFAOYSA-N 0.000 description 2
- NQVPSGXLCXZSTB-UHFFFAOYSA-N CC(C)(C)NC(CCl)=O Chemical compound CC(C)(C)NC(CCl)=O NQVPSGXLCXZSTB-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- GOEUTGSDIAAPHK-OTOKDRCRSA-N N-[3-[2-[1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]pyrimidin-5-yl]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C1=NC=C(C=N1)C=1C=C(C=CC=1)NC(C=C)=O GOEUTGSDIAAPHK-OTOKDRCRSA-N 0.000 description 2
- SRRLFKMFFRPSOF-FDDCHVKYSA-N N-[3-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]anilino]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C1=CC=C(C=C1)NC=1C=C(C=CC=1)NC(C=C)=O SRRLFKMFFRPSOF-FDDCHVKYSA-N 0.000 description 2
- WYSOEBHKGXWUMW-FDDCHVKYSA-N N-[4-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]anilino]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C1=CC=C(C=C1)NC1=CC=C(C=C1)NC(C=C)=O WYSOEBHKGXWUMW-FDDCHVKYSA-N 0.000 description 2
- SIMPGUGWHAZRHG-MHECFPHRSA-N N-[4-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]anilino]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)NC1=CC=C(C=C1)NC(C=C)=O)C=CS2 SIMPGUGWHAZRHG-MHECFPHRSA-N 0.000 description 2
- FFFGEIZWZJBEEN-HTAPYJJXSA-N N-[6-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]thieno[3,2-d]pyrimidin-2-yl]amino]ethyl]anilino]pyridin-3-yl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C=1C2=C(N=C(N=1)N[C@@H](C)C1=CC=C(C=C1)NC1=CC=C(C=N1)NC(C=C)=O)C=CS2 FFFGEIZWZJBEEN-HTAPYJJXSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 102200069690 rs121913500 Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- WXYXPPOCLXRHHG-LBPRGKRZSA-N tert-butyl 4-[5-[(1S)-1-aminoethyl]pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound N[C@@H](C)C=1C=CC(=NC=1)OC1CCN(CC1)C(=O)OC(C)(C)C WXYXPPOCLXRHHG-LBPRGKRZSA-N 0.000 description 2
- JEBYTDJOHLSBKN-BDPMCISCSA-N tert-butyl 4-[5-[1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C=1C=CC(=NC=1)OC1CCN(CC1)C(=O)OC(C)(C)C JEBYTDJOHLSBKN-BDPMCISCSA-N 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- NTFRFLVYBZYHJR-AWEZNQCLSA-N tert-butyl N-[(3S)-1-[(4-nitrophenyl)methyl]piperidin-3-yl]carbamate Chemical compound [N+](=O)([O-])C1=CC=C(CN2C[C@H](CCC2)NC(OC(C)(C)C)=O)C=C1 NTFRFLVYBZYHJR-AWEZNQCLSA-N 0.000 description 2
- GVEWGRYJJXBQKR-UHFFFAOYSA-N tert-butyl N-[1-[5-(3-nitrophenyl)pyrimidin-2-yl]ethyl]carbamate Chemical compound [N+](=O)([O-])C=1C=C(C=CC=1)C=1C=NC(=NC=1)C(C)NC(OC(C)(C)C)=O GVEWGRYJJXBQKR-UHFFFAOYSA-N 0.000 description 2
- DVMHCFBGNOEPLX-UHFFFAOYSA-N tert-butyl n-[1-[(4-nitrophenyl)methyl]piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1CC1=CC=C([N+]([O-])=O)C=C1 DVMHCFBGNOEPLX-UHFFFAOYSA-N 0.000 description 2
- ZZXHVDOVHFUPKJ-UHFFFAOYSA-N tert-butyl n-[1-[(4-nitrophenyl)methyl]pyrrolidin-3-yl]carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCN1CC1=CC=C([N+]([O-])=O)C=C1 ZZXHVDOVHFUPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZZDVSKCYVQHQAH-MAUKXSAKSA-N (4S)-3-[2-[[(1S)-1-(6-piperidin-4-yloxypyridin-3-yl)ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C=1C=NC(=CC=1)OC1CCNCC1 ZZDVSKCYVQHQAH-MAUKXSAKSA-N 0.000 description 1
- KXQOFENFEPXETA-QRWMCTBCSA-N (4S)-3-[2-[[1-[(4-aminophenyl)methyl]pyrrolidin-3-yl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound NC1=CC=C(CN2CC(CC2)NC2=NC=CC(=N2)N2C(OC[C@@H]2C(C)C)=O)C=C1 KXQOFENFEPXETA-QRWMCTBCSA-N 0.000 description 1
- IVFDDVKCCBDPQZ-MSOLQXFVSA-N (7R)-1-[(4-fluorophenyl)methyl]-N-[3-[(1S)-1-hydroxyethyl]phenyl]-7-methyl-5-(1H-pyrrole-2-carbonyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-3-carboxamide Chemical compound C[C@H](O)c1cccc(NC(=O)c2nn(Cc3ccc(F)cc3)c3[C@H](C)CN(Cc23)C(=O)c2ccc[nH]2)c1 IVFDDVKCCBDPQZ-MSOLQXFVSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 1
- ACFFAMJSFZINGL-OWOJBTEDSA-N (e)-4-bromobut-2-enoyl chloride Chemical compound ClC(=O)\C=C\CBr ACFFAMJSFZINGL-OWOJBTEDSA-N 0.000 description 1
- PNVSJQPNBYKJSG-CMLYRFMNSA-N *.B.C=CC(=O)CC1=CC=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOOOOOO Chemical compound *.B.C=CC(=O)CC1=CC=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOOOOOO PNVSJQPNBYKJSG-CMLYRFMNSA-N 0.000 description 1
- PMXXZANXYZJFGU-ZLSHSPGTSA-N *.B.C=CC(=O)CC1=CC=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)N=C1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOOOOO Chemical compound *.B.C=CC(=O)CC1=CC=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)N=C1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOOOOO PMXXZANXYZJFGU-ZLSHSPGTSA-N 0.000 description 1
- YMXAQGOIOHIJJV-WTRPZUJYSA-N *.B.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CN3CCCCC3)C=C2)=NC2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CN3CCNCC3)C=C2)=NC2=C1SC=C2.CCC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOO.[2H]CF.[NaH] Chemical compound *.B.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CN3CCCCC3)C=C2)=NC2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CN3CCNCC3)C=C2)=NC2=C1SC=C2.CCC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOO.[2H]CF.[NaH] YMXAQGOIOHIJJV-WTRPZUJYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- FECNVDHIIJYRIA-UHFFFAOYSA-N 2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)CCC(=O)C(O)=O FECNVDHIIJYRIA-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- NEDJTEXNSTUKHW-UHFFFAOYSA-N 5-bromo-2-methylpyrimidine Chemical compound CC1=NC=C(Br)C=N1 NEDJTEXNSTUKHW-UHFFFAOYSA-N 0.000 description 1
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 1
- FMEBIWNKYZUWFV-UHFFFAOYSA-N 6-chloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)N=C1 FMEBIWNKYZUWFV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101100125460 Arabidopsis thaliana IDH3 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- OBIUFKVNKUKOLE-DOXWZYGJSA-N B=NS.BrC1=CN=C(CN2CCCCC2)N=C1.BrCC1=NC=C(Br)C=N1.C.C.C.C.C.C.C1CCNCC1.C=C(OCC)[Sn](CCCC)(CCCC)CCCC.CC(=O)C1=CN=C(CN2CCCCC2)N=C1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=CN=C(CN2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(CN2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(CN2CCNCC2)N=C1.CC1=NC=C(Br)C=N1 Chemical compound B=NS.BrC1=CN=C(CN2CCCCC2)N=C1.BrCC1=NC=C(Br)C=N1.C.C.C.C.C.C.C1CCNCC1.C=C(OCC)[Sn](CCCC)(CCCC)CCCC.CC(=O)C1=CN=C(CN2CCCCC2)N=C1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=CN=C(CN2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(CN2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(CN2CCNCC2)N=C1.CC1=NC=C(Br)C=N1 OBIUFKVNKUKOLE-DOXWZYGJSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- HYGDGGLNUXTYHS-ZPKPRXFHSA-L BrC1=CN=C(Br)N=C1.BrC1=CN=C(OC2CCCCC2)N=C1.C.C.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C=C(OCC)[Sn](CCCC)(CCCC)CCCC.CC(=O)C1=CN=C(OC2CCCCC2)N=C1.CC(=O)C1=CN=C(OC2CCNCC2)N=C1.CC(C)(C)OC(=O)N1CCC(O)CC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=CN=C(OC2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(OC2CCCCC2)N=C1.Cl[Pd]Cl.[2H]CC Chemical compound BrC1=CN=C(Br)N=C1.BrC1=CN=C(OC2CCCCC2)N=C1.C.C.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C1=CC=C(P(C2=CC=CC=C2)C2=CC=CC=C2)C=C1.C=C(OCC)[Sn](CCCC)(CCCC)CCCC.CC(=O)C1=CN=C(OC2CCCCC2)N=C1.CC(=O)C1=CN=C(OC2CCNCC2)N=C1.CC(C)(C)OC(=O)N1CCC(O)CC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=CN=C(OC2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(OC2CCCCC2)N=C1.Cl[Pd]Cl.[2H]CC HYGDGGLNUXTYHS-ZPKPRXFHSA-L 0.000 description 1
- PIZFJSQPCOTHKJ-ZOKJOEEZSA-N BrC1=CN=C(I)N=C1.C.C.C.C1CCOC1.CC(N)C1=NC=C(Br)C=N1.CC(N=[N+]=[N-])C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(C2=CC=CC([N+](=O)[O-])=C2)C=N1.CC(O)C1=NC=C(Br)C=N1.CC=O.O=[N+]([O-])C1=CC(B(O)O)=CC=C1.[2H]CC Chemical compound BrC1=CN=C(I)N=C1.C.C.C.C1CCOC1.CC(N)C1=NC=C(Br)C=N1.CC(N=[N+]=[N-])C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(C2=CC=CC([N+](=O)[O-])=C2)C=N1.CC(O)C1=NC=C(Br)C=N1.CC=O.O=[N+]([O-])C1=CC(B(O)O)=CC=C1.[2H]CC PIZFJSQPCOTHKJ-ZOKJOEEZSA-N 0.000 description 1
- RDWIQGDPYAPKLZ-OWPGZQOVSA-M BrC1=CN=C(I)N=C1.C.C.C.C1CCOC1.CC(N)C1=NC=C(Br)C=N1.CC(N=[N+]=[N-])C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(N(C)C2=CC=C([N+](=O)[O-])C=C2)C=N1.CC(O)C1=NC=C(Br)C=N1.CC=O.CCC1=CC=C([N+](=O)[O-])C=C1.C[Mg]Cl.[2H]CC Chemical compound BrC1=CN=C(I)N=C1.C.C.C.C1CCOC1.CC(N)C1=NC=C(Br)C=N1.CC(N=[N+]=[N-])C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(Br)C=N1.CC(NC(=O)OC(C)(C)C)C1=NC=C(N(C)C2=CC=C([N+](=O)[O-])C=C2)C=N1.CC(O)C1=NC=C(Br)C=N1.CC=O.CCC1=CC=C([N+](=O)[O-])C=C1.C[Mg]Cl.[2H]CC RDWIQGDPYAPKLZ-OWPGZQOVSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YYJQQGBPUWMHED-CWANUHAESA-N C.C.C.C=CC(=O)Cl.C=CC(=O)N1CCC(OC2=CC=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CC=C(OC2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CC=C(OC2CCNCC2)N=C1.O=S(=O)(I)OOOOO Chemical compound C.C.C.C=CC(=O)Cl.C=CC(=O)N1CCC(OC2=CC=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CC=C(OC2CCCCC2)N=C1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CC=C(OC2CCNCC2)N=C1.O=S(=O)(I)OOOOO YYJQQGBPUWMHED-CWANUHAESA-N 0.000 description 1
- QBQNAYLZSXFZBS-OGKBWZOGSA-N C.C.C.C=CC(=O)Cl.C=CC(=O)NC1=CC=CC(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)=C1.CC(C)(C)OC(=O)NC1=CC=CC(N)=C1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(Br)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC(NC(=O)OC(C)(C)C)=CC=C3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=C3)C=C2)=NC=C1.C[C@H](N)C1=CC=C(Br)C=C1.O=S(=O)(I)OOO Chemical compound C.C.C.C=CC(=O)Cl.C=CC(=O)NC1=CC=CC(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)=C1.CC(C)(C)OC(=O)NC1=CC=CC(N)=C1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(Br)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC(NC(=O)OC(C)(C)C)=CC=C3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=C3)C=C2)=NC=C1.C[C@H](N)C1=CC=C(Br)C=C1.O=S(=O)(I)OOO QBQNAYLZSXFZBS-OGKBWZOGSA-N 0.000 description 1
- HZGLUXIDWPHBLO-RONQZYTMSA-N C.C.C=CC(=O)CC1=CC=C(N(C)C2=CN=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)N=C2)C=C1.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=NC=C(N(C)C2=CC=C([N+](=O)[O-])C=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(N(C)C2=CC=C(N)C=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(N(C)C2=CC=C([N+](=O)[O-])C=C2)C=N1.O=S(=O)(I)OOOOOOOOOO Chemical compound C.C.C=CC(=O)CC1=CC=C(N(C)C2=CN=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)N=C2)C=C1.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=NC=C(N(C)C2=CC=C([N+](=O)[O-])C=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(N(C)C2=CC=C(N)C=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(N(C)C2=CC=C([N+](=O)[O-])C=C2)C=N1.O=S(=O)(I)OOOOOOOOOO HZGLUXIDWPHBLO-RONQZYTMSA-N 0.000 description 1
- RJYZGQYFVVZTSH-CFAHFZLUSA-N C.C.C=CC(=O)Cl.C=CC(=O)NC1=CC(C2=CN=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)N=C2)=CC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=NC=C(C2=CC=CC([N+](=O)[O-])=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(C2=CC=CC(N)=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(C2=CC=CC([N+](=O)[O-])=C2)C=N1.O=S(=O)(I)OOOOOOOOOOO Chemical compound C.C.C=CC(=O)Cl.C=CC(=O)NC1=CC(C2=CN=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)N=C2)=CC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=NC=C(C2=CC=CC([N+](=O)[O-])=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(C2=CC=CC(N)=C2)C=N1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=NC=C(C2=CC=CC([N+](=O)[O-])=C2)C=N1.O=S(=O)(I)OOOOOOOOOOO RJYZGQYFVVZTSH-CFAHFZLUSA-N 0.000 description 1
- LPMJYKYEKREQJT-BGYUAOAQSA-N C.C.C=CC(=O)Cl.CC(C)(C)OC(=O)NC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.CC(C)(C)OC(=O)NC1CCNC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C(N)C=C3)C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C([N+](=O)[O-])C=C3)C2)=NC=C1.NC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.O=[N+]([O-])C1=CC=C(CCl)C=C1.[HH] Chemical compound C.C.C=CC(=O)Cl.CC(C)(C)OC(=O)NC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.CC(C)(C)OC(=O)NC1CCNC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C(N)C=C3)C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C([N+](=O)[O-])C=C3)C2)=NC=C1.NC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.O=[N+]([O-])C1=CC=C(CCl)C=C1.[HH] LPMJYKYEKREQJT-BGYUAOAQSA-N 0.000 description 1
- NRYDTPCYAOMIJC-VUUKWDJASA-N C.C.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=C3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C([N+](=O)[O-])C=C3)C=C2)=NC=C1.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.NC1=CC=C([N+](=O)[O-])C=C1 Chemical compound C.C.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=C3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C([N+](=O)[O-])C=C3)C=C2)=NC=C1.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.NC1=CC=C([N+](=O)[O-])C=C1 NRYDTPCYAOMIJC-VUUKWDJASA-N 0.000 description 1
- JOPIOVLNBHACIQ-LCTJFXLKSA-N C.C.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=NC=C(N)C=C3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=NC=C([N+](=O)[O-])C=C3)C=C2)=NC=C1.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=NC=C([N+](=O)[O-])C=C2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=NC=C([N+](=O)[O-])C=C2)C=C1.NC1=NC=C([N+](=O)[O-])C=C1 Chemical compound C.C.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=NC=C(N)C=C3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=NC=C([N+](=O)[O-])C=C3)C=C2)=NC=C1.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=NC=C([N+](=O)[O-])C=C2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=NC=C([N+](=O)[O-])C=C2)C=C1.NC1=NC=C([N+](=O)[O-])C=C1 JOPIOVLNBHACIQ-LCTJFXLKSA-N 0.000 description 1
- DSVQBKYZISSDLY-XOLSJLRUSA-N C.C.CC(=O)C1=CC=C(Cl)N=C1.CC(=O)C1=CC=C(OC2CCCCC2)N=C1.CC(C)(C)OC(=O)N1CCC(O)CC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=CC=C(OC2CCCCC2)N=C1.CC1=CC=CC=C1.COC(=O)CC(=O)OC.O=C(Cl)C1=CC=C(Cl)N=C1.O=C(O)C1=CC=C(Cl)N=C1.O=S(Cl)Cl Chemical compound C.C.CC(=O)C1=CC=C(Cl)N=C1.CC(=O)C1=CC=C(OC2CCCCC2)N=C1.CC(C)(C)OC(=O)N1CCC(O)CC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(N)C1=CC=C(OC2CCCCC2)N=C1.CC1=CC=CC=C1.COC(=O)CC(=O)OC.O=C(Cl)C1=CC=C(Cl)N=C1.O=C(O)C1=CC=C(Cl)N=C1.O=S(Cl)Cl DSVQBKYZISSDLY-XOLSJLRUSA-N 0.000 description 1
- FVUAODUFYHWZGB-BYLJZHBASA-M C.C1CCOC1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.COC(=O)C1=CC=C([C@H](C)N)C=C1.COC(=O)C1=CC=C([C@H](C)NC(=O)OC(C)(C)C)C=C1.CS(=O)(=O)Cl.C[C@H](N)C1=CC=C(CN2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CCl)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CN2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CO)C=C1.O=C(OCC1=CC=CC=C1)N1CCNCC1.O=COO[K].[KH] Chemical compound C.C1CCOC1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.COC(=O)C1=CC=C([C@H](C)N)C=C1.COC(=O)C1=CC=C([C@H](C)NC(=O)OC(C)(C)C)C=C1.CS(=O)(=O)Cl.C[C@H](N)C1=CC=C(CN2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CCl)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CN2CCCCC2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(CO)C=C1.O=C(OCC1=CC=CC=C1)N1CCNCC1.O=COO[K].[KH] FVUAODUFYHWZGB-BYLJZHBASA-M 0.000 description 1
- PAZBQKFFEGQUJU-HJYJCNRFSA-N C.C=CC(=O)Cl.C=CC(=O)N1CCC(OC2=NC=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(OC2CCNCC2)N=C1.O=S(=O)(I)OOOOOOOOO Chemical compound C.C=CC(=O)Cl.C=CC(=O)N1CCC(OC2=NC=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.CC(NC1=NC=CC(N2C(=O)OC[C@@H]2C(C)C)=N1)C1=CN=C(OC2CCNCC2)N=C1.O=S(=O)(I)OOOOOOOOO PAZBQKFFEGQUJU-HJYJCNRFSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- XETZAFUQGNPDGY-DFBAGOPYSA-N C=CC(=C)CC1=CC=C(CC2=CC=C([C@H](C)CC3=CC=CC(C4C(=C)CC[C@@H]4C(C)C)=C3)C=C2)C=C1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)NC1=CC=C(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)NC1=CC=CC(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CN3CCN(C(=O)/C=C/CN(C)C)CC3)C=C2)=NC=C1 Chemical compound C=CC(=C)CC1=CC=C(CC2=CC=C([C@H](C)CC3=CC=CC(C4C(=C)CC[C@@H]4C(C)C)=C3)C=C2)C=C1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)NC1=CC=C(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)NC1=CC=CC(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CN3CCN(C(=O)/C=C/CN(C)C)CC3)C=C2)=NC=C1 XETZAFUQGNPDGY-DFBAGOPYSA-N 0.000 description 1
- OXRNFQAQHHUTLK-ATANZVAHSA-N C=CC(=C)N1CCC(CC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCNCC3)C=C2)=NC=C1.O=[SH]I Chemical compound C=CC(=C)N1CCC(CC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCNCC3)C=C2)=NC=C1.O=[SH]I OXRNFQAQHHUTLK-ATANZVAHSA-N 0.000 description 1
- MOYVTYXAZQGUHA-UHFFFAOYSA-N C=CC(=O)CC1=CC=C(C(C)C)C=C1.C=CC(=O)CC1=CC=CC(C(C)C)=C1.C=CC(=O)CC1=CC=CC(NC(C)C)=C1.C=CC(=O)CC1=CC=CC(OC(C)C)=C1.C=CC(=O)N1CC(N(C)CC(C)C)C1.C=CC(=O)N1CC=C(COC(C)C)C1.C=CC(=O)N1CCC(N(C)CC(C)C)CC1.C=CC(=O)N1CCC(NC(C)C)CC1.C=CC(=O)N1CCC2(CC1)CN(CC(C)C)C2.C=CC(=O)N1CCN(C(C)C)CC1.C=CC(=O)N1CCN(C)CC1.C=CC(=O)NC1=CC=C(NC(C)C)C=C1.C=CC(=O)NC1=CC=C(OC(C)C)C=C1.C=CC(=O)NC1=CN=C(NC(C)C)C=C1 Chemical compound C=CC(=O)CC1=CC=C(C(C)C)C=C1.C=CC(=O)CC1=CC=CC(C(C)C)=C1.C=CC(=O)CC1=CC=CC(NC(C)C)=C1.C=CC(=O)CC1=CC=CC(OC(C)C)=C1.C=CC(=O)N1CC(N(C)CC(C)C)C1.C=CC(=O)N1CC=C(COC(C)C)C1.C=CC(=O)N1CCC(N(C)CC(C)C)CC1.C=CC(=O)N1CCC(NC(C)C)CC1.C=CC(=O)N1CCC2(CC1)CN(CC(C)C)C2.C=CC(=O)N1CCN(C(C)C)CC1.C=CC(=O)N1CCN(C)CC1.C=CC(=O)NC1=CC=C(NC(C)C)C=C1.C=CC(=O)NC1=CC=C(OC(C)C)C=C1.C=CC(=O)NC1=CN=C(NC(C)C)C=C1 MOYVTYXAZQGUHA-UHFFFAOYSA-N 0.000 description 1
- KCHRNNJPRHDSAD-UHFFFAOYSA-N C=CC(=O)CC1=CC=C(C(C)C)C=C1.C=CC(=O)CC1=CC=CC(C(C)C)=C1.C=CC(=O)CC1=CC=CC(NC(C)C)=C1.C=CC(=O)CC1=CC=CC(OC(C)C)=C1.C=CC(=O)N1CC(N(C)CC(C)C)C1.C=CC(=O)N1CC=C(COC(C)C)C1.C=CC(=O)N1CCC(N(C)CC(C)C)CC1.C=CC(=O)N1CCC(NC(C)C)CC1.C=CC(=O)N1CCC2(CC1)CN(CC(C)C)C2.C=CC(=O)N1CCN(C(C)C)CC1.C=CC(=O)N1CCN(C)CC1.C=CC(=O)NC1=CC=C(NC(C)C)C=C1.C=CC(=O)NC1=CC=C(OC(C)C)C=C1.C=CC(=O)NC1=CN=C(NC(C)C)C=C1.CC(=O)NC1=CC=C(NC(C)C)C=C1 Chemical compound C=CC(=O)CC1=CC=C(C(C)C)C=C1.C=CC(=O)CC1=CC=CC(C(C)C)=C1.C=CC(=O)CC1=CC=CC(NC(C)C)=C1.C=CC(=O)CC1=CC=CC(OC(C)C)=C1.C=CC(=O)N1CC(N(C)CC(C)C)C1.C=CC(=O)N1CC=C(COC(C)C)C1.C=CC(=O)N1CCC(N(C)CC(C)C)CC1.C=CC(=O)N1CCC(NC(C)C)CC1.C=CC(=O)N1CCC2(CC1)CN(CC(C)C)C2.C=CC(=O)N1CCN(C(C)C)CC1.C=CC(=O)N1CCN(C)CC1.C=CC(=O)NC1=CC=C(NC(C)C)C=C1.C=CC(=O)NC1=CC=C(OC(C)C)C=C1.C=CC(=O)NC1=CN=C(NC(C)C)C=C1.CC(=O)NC1=CC=C(NC(C)C)C=C1 KCHRNNJPRHDSAD-UHFFFAOYSA-N 0.000 description 1
- ZANLZGYTUOTPJN-RKSYTCEXSA-N C=CC(=O)CC1=CC=C(CN2CCC[C@H](NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C2)C=C1.C=CC(=O)Cl.CC(C)(C)OC(=O)N[C@H]1CCCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.CC(C)(C)OC(=O)N[C@H]1CCCNC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@H]2CCCN(CC3=CC=C(N)C=C3)C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@H]2CCCN(CC3=CC=C([N+](=O)[O-])C=C3)C2)=NC=C1.N[C@H]1CCCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.O=S(=O)(I)OOOOOOO.O=[N+]([O-])C1=CC=C(CCl)C=C1.[HH] Chemical compound C=CC(=O)CC1=CC=C(CN2CCC[C@H](NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C2)C=C1.C=CC(=O)Cl.CC(C)(C)OC(=O)N[C@H]1CCCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.CC(C)(C)OC(=O)N[C@H]1CCCNC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@H]2CCCN(CC3=CC=C(N)C=C3)C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@H]2CCCN(CC3=CC=C([N+](=O)[O-])C=C3)C2)=NC=C1.N[C@H]1CCCN(CC2=CC=C([N+](=O)[O-])C=C2)C1.O=S(=O)(I)OOOOOOO.O=[N+]([O-])C1=CC=C(CCl)C=C1.[HH] ZANLZGYTUOTPJN-RKSYTCEXSA-N 0.000 description 1
- BVPBKUFJVVARCU-XCURNFNKSA-N C=CC(=O)Cl.C=CC(=O)N1CCN(CC2=NC=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.O=S(=O)(I)OOOO Chemical compound C=CC(=O)Cl.C=CC(=O)N1CCN(CC2=NC=C(C(C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.O=S(=O)(I)OOOO BVPBKUFJVVARCU-XCURNFNKSA-N 0.000 description 1
- YKVFBTRSQBACQJ-CWKGECCZSA-N C=CC(=O)Cl.CC(C)(C)OC(=O)N1CCC(N)CC1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1/C1=N/C(N[C@@H](C)C2=CC=C(Br)C=C2)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=C2SC=CC2=NC(N[C@@H](C)C2=CC=C(NC3CCN(C(=O)OC(C)(C)C)CC3)C=C2)=N1.CC([H]C1=NC(N2C(=O)OC[C@@H]2C(C)C)=C2SC=CC2=N1)C1=CC=C([H]C2CCNCC2)C=C1.C[C@H](N)C1=CC=C(Br)C=C1 Chemical compound C=CC(=O)Cl.CC(C)(C)OC(=O)N1CCC(N)CC1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1/C1=N/C(N[C@@H](C)C2=CC=C(Br)C=C2)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=C2SC=CC2=NC(N[C@@H](C)C2=CC=C(NC3CCN(C(=O)OC(C)(C)C)CC3)C=C2)=N1.CC([H]C1=NC(N2C(=O)OC[C@@H]2C(C)C)=C2SC=CC2=N1)C1=CC=C([H]C2CCNCC2)C=C1.C[C@H](N)C1=CC=C(Br)C=C1 YKVFBTRSQBACQJ-CWKGECCZSA-N 0.000 description 1
- GFPJHBIANUEBGD-VYQQCQRLSA-N C=CC(=O)Cl.CC(C)(C)OC(=O)NC1CCNCC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C(N)C=C3)CC2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C([N+](=O)[O-])C=C3)CC2)=NC=C1.CC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)CC1.NC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)CC1.O=[N+]([O-])C1=CC=C(CCl)C=C1.[HH] Chemical compound C=CC(=O)Cl.CC(C)(C)OC(=O)NC1CCNCC1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C(N)C=C3)CC2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(NC2CCN(CC3=CC=C([N+](=O)[O-])C=C3)CC2)=NC=C1.CC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)CC1.NC1CCN(CC2=CC=C([N+](=O)[O-])C=C2)CC1.O=[N+]([O-])C1=CC=C(CCl)C=C1.[HH] GFPJHBIANUEBGD-VYQQCQRLSA-N 0.000 description 1
- RGQBHHGOACWGNG-IPJKLNLHSA-N C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=N3)C=C2)=NC2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C([N+](=O)[O-])C=N3)C=C2)=NC2=C1SC=C2.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=N2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=N2)C=C1.NC1=NC=C([N+](=O)[O-])C=C1 Chemical compound C=CC(=O)Cl.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=N3)C=C2)=NC2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C([N+](=O)[O-])C=N3)C=C2)=NC2=C1SC=C2.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=N2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=N2)C=C1.NC1=NC=C([N+](=O)[O-])C=C1 RGQBHHGOACWGNG-IPJKLNLHSA-N 0.000 description 1
- VNZOEWASCLXQOB-BVXBEDHZSA-N C=CC(=O)N1CCC(NC2=CC=C([C@H](C)NC3=NC(N4C(=O)OC[C@@H]4C(C)C)=C4SC=CC4=N3)C=C2)CC1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOOOOOOO Chemical compound C=CC(=O)N1CCC(NC2=CC=C([C@H](C)NC3=NC(N4C(=O)OC[C@@H]4C(C)C)=C4SC=CC4=N3)C=C2)CC1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.ClC1=N/C2=C(SC=C2)/C(Cl)=N\1.O=S(=O)(I)OOOOOOOOOOOOOOOOO VNZOEWASCLXQOB-BVXBEDHZSA-N 0.000 description 1
- BIPURBQKYZOJTK-WHRBVRGCSA-N C=CC(=O)N1CCC(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(NC=N4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)NC1=CC=C(NC2=CN=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)NC1=CC=C(OC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1 Chemical compound C=CC(=O)N1CCC(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(NC=N4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)NC1=CC=C(NC2=CN=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)NC1=CC=C(OC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1 BIPURBQKYZOJTK-WHRBVRGCSA-N 0.000 description 1
- WABGYDOAKZUOQM-FXAWDEMLSA-N C=CC(=O)N1CCC(OC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1 Chemical compound C=CC(=O)N1CCC(OC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1 WABGYDOAKZUOQM-FXAWDEMLSA-N 0.000 description 1
- JWTZNBJNUQHTKD-DURCLVMGSA-N C=CC(=O)N1CCC(OC2=NC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.C=CC(=O)N1CCN(OC2=NC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1 Chemical compound C=CC(=O)N1CCC(OC2=NC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1.C=CC(=O)N1CCN(OC2=NC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=N2)CC1 JWTZNBJNUQHTKD-DURCLVMGSA-N 0.000 description 1
- BPLDSOKPQFMANW-WNYDHQBMSA-N C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(NC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(OC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)NC1=CC=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)NC1=CN=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1 Chemical compound C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(NC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(OC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)CC1.C=CC(=O)NC1=CC=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1.C=CC(=O)NC1=CN=C(NC2=CC=C([C@H](C)NC3=NC4=C(SC=C4)C(N4C(=O)CC[C@@H]4C(C)C)=N3)C=C2)C=C1 BPLDSOKPQFMANW-WNYDHQBMSA-N 0.000 description 1
- NNEYDJZHHSDDOX-XLKUURNXSA-N C=CC(=O)NC1=CC(C2=CN=C([C@H](C)NC3=NC=CC(N4C(=O)CC[C@@H]4C(C)C)=N3)N=C2)=CC=C1.C=CC(=O)NC1=CC=C(N(C)C2=CN=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)N=C2)C=C1 Chemical compound C=CC(=O)NC1=CC(C2=CN=C([C@H](C)NC3=NC=CC(N4C(=O)CC[C@@H]4C(C)C)=N3)N=C2)=CC=C1.C=CC(=O)NC1=CC=C(N(C)C2=CN=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)N=C2)C=C1 NNEYDJZHHSDDOX-XLKUURNXSA-N 0.000 description 1
- LIYKIMJNEGQJQW-TVEITMRYSA-N C=CC(=O)NC1=CC=C(CN2CCC(NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C2)C=C1.O=S(=O)(I)OOOOOOOO Chemical compound C=CC(=O)NC1=CC=C(CN2CCC(NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C2)C=C1.O=S(=O)(I)OOOOOOOO LIYKIMJNEGQJQW-TVEITMRYSA-N 0.000 description 1
- ZAGRDYUWATZNEL-ZMBIFBSDSA-N C=CC(=O)NC1=CC=C(CN2CCC(NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)CC2)C=C1.O=S(=O)(I)OOOOOO Chemical compound C=CC(=O)NC1=CC=C(CN2CCC(NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)CC2)C=C1.O=S(=O)(I)OOOOOO ZAGRDYUWATZNEL-ZMBIFBSDSA-N 0.000 description 1
- OWFAVYCTFYHBGP-KKECBTDNSA-N C=CC(=O)NC1=CC=C(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.ClC1=NC(Cl)=NC=C1.O=S(=O)(I)OO Chemical compound C=CC(=O)NC1=CC=C(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.ClC1=NC(Cl)=NC=C1.O=S(=O)(I)OO OWFAVYCTFYHBGP-KKECBTDNSA-N 0.000 description 1
- MNCMLUCLYZQPPW-GYVWTIIVSA-N C=CC(=O)NC1=CN=C(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.ClC1=NC(Cl)=NC=C1.O=S(=O)(O)I Chemical compound C=CC(=O)NC1=CN=C(NC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)C=C1.CC(C)[C@H]1COC(=O)N1.CC(C)[C@H]1COC(=O)N1C1=NC(Cl)=NC=C1.ClC1=NC(Cl)=NC=C1.O=S(=O)(O)I MNCMLUCLYZQPPW-GYVWTIIVSA-N 0.000 description 1
- BEWLUEOYYPKPQL-PGRDOPGGSA-N CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1 Chemical compound CC(=O)N1CCN(CC2=CC=C([C@H](C)NC3=NC=CC(N4C(=O)OC[C@@H]4C(C)C)=N3)C=C2)CC1 BEWLUEOYYPKPQL-PGRDOPGGSA-N 0.000 description 1
- IAMUZPIBDZQLCL-HWYHQIOXSA-N CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=C3)C=C2)=NC2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C([N+](=O)[O-])C=C3)C=C2)=NC2=C1SC=C2.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.NC1=CC=C([N+](=O)[O-])C=C1 Chemical compound CC(C)[C@H]1COC(=O)N1/C1=N/C(Cl)=N\C2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C(N)C=C3)C=C2)=NC2=C1SC=C2.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(NC3=CC=C([N+](=O)[O-])C=C3)C=C2)=NC2=C1SC=C2.C[C@H](N)C1=CC=C(Br)C=C1.C[C@H](N)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(Br)C=C1.C[C@H](NC(=O)OC(C)(C)C)C1=CC=C(NC2=CC=C([N+](=O)[O-])C=C2)C=C1.NC1=CC=C([N+](=O)[O-])C=C1 IAMUZPIBDZQLCL-HWYHQIOXSA-N 0.000 description 1
- OFSPZYMQHPXUEX-GLHSYOQJSA-N CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCN(C(=O)/C=C/CN(C)C)CC3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCNCC3)C=C2)=NC=C1.O=C(Cl)/C=C/CBr.O=[SH](=O)I Chemical compound CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCN(C(=O)/C=C/CN(C)C)CC3)C=C2)=NC=C1.CC(C)[C@H]1COC(=O)N1C1=NC(N[C@@H](C)C2=CC=C(CC3CCNCC3)C=C2)=NC=C1.O=C(Cl)/C=C/CBr.O=[SH](=O)I OFSPZYMQHPXUEX-GLHSYOQJSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101100125468 Homo sapiens IDH1 gene Proteins 0.000 description 1
- 101100452039 Homo sapiens IDH2 gene Proteins 0.000 description 1
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101710175291 Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- UNFRZFZQPKRERR-LEWJYISDSA-N N-[4-[[(3S)-3-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]piperidin-1-yl]methyl]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H]1CN(CCC1)CC1=CC=C(C=C1)NC(C=C)=O UNFRZFZQPKRERR-LEWJYISDSA-N 0.000 description 1
- BNAVSPUCXDUAPS-GFOWMXPYSA-N N-[4-[[3-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC1CN(CC1)CC1=CC=C(C=C1)NC(C=C)=O BNAVSPUCXDUAPS-GFOWMXPYSA-N 0.000 description 1
- OZQBHUKRBFHLCM-OAQYLSRUSA-N N-[4-[[4-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]piperidin-1-yl]methyl]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC1CCN(CC1)CC1=CC=C(C=C1)NC(C=C)=O OZQBHUKRBFHLCM-OAQYLSRUSA-N 0.000 description 1
- AARMUQGCFQLROD-FBLFFUNLSA-N N-[4-[methyl-[2-[1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]pyrimidin-5-yl]amino]phenyl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)NC(C)C1=NC=C(C=N1)N(C1=CC=C(C=C1)NC(C=C)=O)C AARMUQGCFQLROD-FBLFFUNLSA-N 0.000 description 1
- LXPKJCWWTSKVEO-LAUBAEHRSA-N N-[6-[4-[(1S)-1-[[4-[(4S)-2-oxo-4-propan-2-yl-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]anilino]pyridin-3-yl]prop-2-enamide Chemical compound C(C)(C)[C@@H]1N(C(OC1)=O)C1=NC(=NC=C1)N[C@@H](C)C1=CC=C(C=C1)NC1=CC=C(C=N1)NC(C=C)=O LXPKJCWWTSKVEO-LAUBAEHRSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010062636 apomyoglobin Proteins 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 125000005876 benzo[b][1,4]oxazinyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002170 ethers Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005866 methoxyethanyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XIFJZJPMHNUGRA-UHFFFAOYSA-N n-methyl-4-nitroaniline Chemical compound CNC1=CC=C([N+]([O-])=O)C=C1 XIFJZJPMHNUGRA-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- GDCOSERQIWBYOR-UHFFFAOYSA-N tert-butyl 4-[5-(1-aminoethyl)pyrimidin-2-yl]oxypiperidine-1-carboxylate Chemical compound NC(C)C=1C=NC(=NC=1)OC1CCN(CC1)C(=O)OC(C)(C)C GDCOSERQIWBYOR-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- IEUIEMIRUXSXCL-UHFFFAOYSA-N tert-butyl n-(3-aminophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(N)=C1 IEUIEMIRUXSXCL-UHFFFAOYSA-N 0.000 description 1
- WUOQXNWMYLFAHT-QMMMGPOBSA-N tert-butyl n-[(3s)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCNC1 WUOQXNWMYLFAHT-QMMMGPOBSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000002366 time-of-flight method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the invention generally relates to therapeutics and treatment methods for certain diseases and conditions. More particularly, the invention provides novel chemical compounds and pharmaceutical compositions thereof useful for treating cancer and methods of preparation and use thereof.
- Isocitrate dehydrogenase is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate ( ⁇ -ketoglutarate) and CO 2 .
- IDH exists in three isoforms in humans: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria.
- the isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+.
- IDHs localize to the cytosol as well as the mitochondrion and peroxisome.
- IDH normal, wild type IDH enzymes help to break down nutrients and generate energy for cells.
- IDH creates a molecule that alters the cells' genetic programming, and instead of maturing, the cells remain primitive and proliferate quickly.
- Non-mutant IDH 1/2 catalyzes the oxidative decarboxylation of isocitrate to ⁇ -ketoglutarate ( ⁇ -KG) thereby reducing NAD+(NADP+) to NADP (NADPH), e.g., in the forward reaction.
- IDH1 and IDH2 are mutated in a wide range of hematologic and solid tumor malignancies. Mutations of IDH 1/2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of -ketoglutarate to R ( ⁇ )-2-hydroxyglutarate (2HG), which is not formed by wild-type IDH 1/2.
- Human IDH2 gene encodes a protein of 452 amino acids. (GenBank entries NM_002168.2 and NP 002159.2; The MGC Project Team 2004 , Genome Res. 14:2121-2127).
- Human IDH1 gene encodes a protein of 414 amino acids (GenBank entries NM_005896.2 and NP 005887.2; Nekrutenko et al, 1998 Mol. Biol. Evol. 15:1674-1684; Geisbrecht et al, 1999 J. Biol. Chem. 274:30527-30533; Wiemann et al, 2001 Genome Res. 11:422-435; The MGC Project Team 2004 Genome Res. 14:2121-2127; Sjoeblom et al. 2006 Science 314:268-274.) 2HG production is believed to contribute to the formation and progression of cancer. (Dang, et al. 2009 Nature 462:739-44.)
- the invention provides novel, orally available, selective and potent inhibitors of mutated IDH 1 and/or IDH 2 proteins.
- the compounds disclosed here form irreversible covalent bond with mutant IDH 1 and/or IDH 2 protein and effectively inhibit their respective alpha hydroxyl activity.
- the invention generally relates to a compound having the structure of formula (I)
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- R E is a group comprising an electrophilic warhead
- R E comprises a group selected from:
- the compound has the structural formula (II):
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moieties and/or comprises an electrophilic warhead selected from:
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moiety and/or comprises of an electrophilic group selected from:
- the invention generally relates to a pharmaceutical composition.
- the pharmaceutical composition includes a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent.
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound having the structural formula of (I):
- each of R A and R B is independently H or a halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- R E is a group comprising an electrophilic warhead
- R E of the compound comprises a group selected from:
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound having the structural formula of (II):
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound having the structural formula of (III):
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- the invention generally relates to a method for treating, reducing, or preventing a disease or disorder.
- the method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- R E is a group comprising an electrophilic warhead
- the invention generally relates to a method for treating, reducing, or preventing a disease or disorder.
- the method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (II):
- each of R A and R B is independently H or a halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the invention generally relates to a method for treating, reducing, or preventing a disease or disorder.
- the method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (III):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- FIG. 1 shows exemplary Intact Mass spectrum of IDH1 R132C and labeled Mass Spectrum of IDH1 R132C treated with ISO1 and ISO3, respectively.
- FIG. 2 shows exemplary Intact Mass of IDH1 R132C.
- FIG. 3 shows exemplary Labeled Mass Spectrum of IDH1 R132C treated with ISO1.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- administration encompasses the delivery to a subject of a compound as described herein, or a prodrug or other pharmaceutically acceptable derivative thereof, using any suitable formulation or route of administration, as discussed herein.
- electrophilic group refers to group or moiety that is attracted towards and capable of accepting a pair of electrons to form a new covalent bond.
- electrophilic groups include an acrylamide group.
- the terms “effective amount” or “therapeutically effective amount” refer to that amount of a compound or pharmaceutical composition described herein that is sufficient to effect the intended application including, but not limited to, disease treatment, as illustrated below.
- the amount is that effective for detectable killing or inhibition of the growth or spread of cancer cells; the size or number of tumors; or other measure of the level, stage, progression or severity of the cancer.
- the therapeutically effective amount can vary depending upon the intended application, or the subject and disease condition being treated, e.g., the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the weight and age of the patient, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells, e.g., reduction of cell migration.
- the specific dose will vary depending on, for example, the particular compounds chosen, the species of subject and their age/existing health conditions or risk for health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- treatment refers to a method of reducing, delaying or ameliorating such a condition before or after it has occurred.
- Treatment may be directed at one or more effects or symptoms of a disease and/or the underlying pathology.
- Treatment is aimed to obtain beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit.
- therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
- a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disorder.
- the pharmaceutical compounds and/or compositions can be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
- the treatment can be any reduction and can be, but is not limited to, the complete ablation of the disease or the symptoms of the disease.
- reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
- the term “therapeutic effect” refers to a therapeutic benefit and/or a prophylactic benefit as described herein.
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Such esters can act as a prodrug as defined herein.
- Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfinic acids, sulfonic acids and boronic acids.
- esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
- the esters can be formed with a hydroxy or carboxylic acid group of the parent compound.
- enol ethers include, but are not limited to, derivatives of formula —C ⁇ C(OR) where R can be selected from alkyl, alkenyl, alkynyl, aryl, aralkyl and cycloalkyl.
- pharmaceutically acceptable enol esters include, but are not limited to, derivatives of formula —C ⁇ C(OC(O)R) where R can be selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl and cycloalkyl.
- a “pharmaceutically acceptable form” of a disclosed compound includes, but is not limited to, pharmaceutically acceptable salts, esters, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives of disclosed compounds.
- a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, esters, isomers, prodrugs and isotopically labeled derivatives of disclosed compounds.
- a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, esters, stereoisomers, prodrugs and isotopically labeled derivatives of disclosed compounds.
- the pharmaceutically acceptable form is a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19.
- Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchioric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchioric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate,
- organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoracetic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- the salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of a parent compound with a suitable base or acid, respectively.
- Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
- compositions include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
- the pharmaceutically acceptable base addition salt can be chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
- the pharmaceutically acceptable form is a “solvate” (e.g., a hydrate).
- solvate refers to compounds that further include a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces.
- the solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. Where the solvent is water, the solvate is a “hydrate”.
- Pharmaceutically acceptable solvates and hydrates are complexes that, for example, can include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3 or about 4, solvent or water molecules. It will be understood that the term “compound” as used herein encompasses the compound and solvates of the compound, as well as mixtures thereof.
- the pharmaceutically acceptable form is a prodrug.
- prodrug refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound.
- a prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood).
- hydrolysis e.g., hydrolysis in blood
- a prodrug has improved physical and/or delivery properties over the parent compound.
- Prodrugs can increase the bioavailability of the compound when administered to a subject (e.g., by permitting enhanced absorption into the blood following oral administration) or which enhance delivery to a biological compartment of interest (e.g., the brain or lymphatic system) relative to the parent compound.
- exemplary prodrugs include derivatives of a disclosed compound with enhanced aqueous solubility or active transport through the gut membrane, relative to the parent compound.
- the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
- a discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design , ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
- Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it can enhance absorption from the digestive tract, or it can enhance drug stability for long-term storage.
- the term “pharmaceutically acceptable” excipient, carrier, or diluent refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.
- a pharmaceutically acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ring
- wetting agents such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymer as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- the term “subject” refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment.
- the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.
- Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 95% (“substantially pure”), which is then used or formulated as described herein. In certain embodiments, the compounds of the present invention are more than 99% pure.
- Solvates and polymorphs of the compounds of the invention are also contemplated herein.
- Solvates of the compounds of the present invention include, for example, hydrates.
- C 1-6 alkyl is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , and C 5-6 alkyl.
- alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C 1-10 alkyl).
- a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
- alkyl can be a C 1-6 alkyl group. In some embodiments, alkyl groups have 1 to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms.
- Representative saturated straight chain alkyls include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like.
- alkyl is attached to the parent molecule by a single bond.
- an alkyl group is optionally substituted by one or more of substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfona
- a substituted alkyl can be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl, and phenethyl.
- alkoxy refers to the group —O-alkyl, including from 1 to 10 carbon atoms (C 1-10 ) of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C 1-3 alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 3 carbon atoms.
- an alkoxy group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate
- aromatic refers to a radical with 6 to 14 ring atoms (e.g., C 6-14 aromatic or C 6-14 aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl).
- the aryl is a C 6-10 aryl group.
- bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
- bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in“-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
- a numerical range such as “6 to 14 aryl” refers to each integer in the given range; e.g., “6 to 14 ring atoms” means that the aryl group can consist of 6 ring atoms, 7 ring atoms, etc., up to and including 14 ring atoms.
- the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups.
- Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In a multi-ring group, only one ring is required to be aromatic, so groups such as indanyl are encompassed by the aryl definition.
- Non-limiting examples of aryl groups include phenyl, phenalenyl, naphthalenyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like.
- an aryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfon
- cycloalkyl and “carbocyclyl” each refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated.
- Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or “cycloalkynyl” if the carbocycle contains at least one triple bond.
- Cycloalkyl groups include groups having from 3 to 13 ring atoms (i.e., C 3-13 cycloalkyl).
- a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 13 carbon atoms” means that the cycloalkyl group can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 13 carbon atoms.
- the term “cycloalkyl” also includes bridged and spiro-fused cyclic structures containing no heteroatoms.
- the term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups.
- Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like.
- cycloalkyl can be a C 3-8 cycloalkyl radical. In some embodiments, “cycloalkyl” can be a C 3-5 cycloalkyl radical.
- Illustrative examples of cycloalkyl groups include, but are not limited to the following moieties: C 3-6 carbocyclyl groups include, without limitation, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ) and the like.
- C 3-7 carbocyclyl groups include norbornyl (C 7 ).
- Examples of C 3-8 carbocyclyl groups include the aforementioned C 3-7 carbocyclyl groups as well as cycloheptyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like.
- C 3-13 carbocyclyl groups include the aforementioned C 3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like.
- a cycloalkyl group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, s
- cycloalkenyl and cycloalkynyl mirror the above description of “cycloalkyl” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl” or “alkynyl” terms are as described herein.
- a cycloalkenyl group can have 3 to 13 ring atoms, such as 5 to 8 ring atoms.
- a cycloalkynyl group can have 5 to 13 ring atoms.
- halide means fluoro, chloro, bromo or iodo.
- haloalkyl means fluoro, chloro, bromo or iodo.
- haloalkenyl means fluoro, chloro, bromo or iodo.
- haloalkynyl means alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof.
- fluoroalkyl and fluoroalkoxy include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
- halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
- alkyl, alkenyl, alkynyl and alkoxy groups are as defined herein and can be optionally further substituted as defined herein.
- heteroalkyl refers to an alkyl radical, which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
- a numerical range can be given, e.g., C 1-4 heteroalkyl which refers to the chain length in total, which in this example is 4 atoms long.
- a —CH 2 OCH 2 CH 3 radical is referred to as a “C 4 ” heteroalkyl, which includes the heteroatom center in the atom chain length description.
- Connection to the parent molecular structure can be through either a heteroatom or a carbon in the heteroalkyl chain.
- an N-containing heteroalkyl moiety refers to a group in which at least one of the skeletal atoms is a nitrogen atom.
- One or more heteroatom(s) in the heteroalkyl radical can be optionally oxidized.
- One or more nitrogen atoms, if present, can also be optionally quaternized.
- heteroalkyl also includes skeletal chains substituted with one or more nitrogen oxide (—O—) substituents.
- heteroalkyl groups include, without limitation, ethers such as methoxyethanyl (—CH 2 CH 2 OCH 3 ), ethoxymethanyl (—CH 2 OCH 2 CH 3 ), (methoxymethoxy)ethanyl (—CH 2 CH 2 OCH 2 OCH 3 ), (methoxymethoxy) methanyl (—CH 2 OCH 2 OCH 3 ) and (methoxyethoxy)methanyl (—CH 2 OCH 2 CH 2 OCH 3 ) and the like; amines such as (—CH 2 CH 2 NHCH 3 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 NHCH 2 CH 3 , —CH 2 N(CH 2 CH 3 )(CH 3 )) and the like.
- ethers such as methoxyethanyl (—CH 2 CH 2 OCH 3 ), ethoxymethanyl (—CH 2 OCH 2 CH 3 ), (methoxymethoxy)ethany
- heteroaryl or, alternatively, “heteroaromatic” refers to a refers to a radical of a 5-18 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic and the like) aromatic ring system (e.g., having 6, 10 or 14 ⁇ electrons shared in a cyclic array) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur (“5-18 membered heteroaryl”).
- Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings.
- a numerical range such as “5 to 18” refers to each integer in the given range; e.g., “5 to 18 ring atoms” means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some instances, a heteroaryl can have 5 to 14 ring atoms.
- the heteroaryl has, for example, bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-ene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylene.
- an N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.
- One or more heteroatom(s) in the heteroaryl radical can be optionally oxidized.
- One or more nitrogen atoms, if present, can also be optionally quaternized.
- Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (—O—) substituents, such as pyridinyl N-oxides. The heteroaryl is attached to the parent molecular structure through any atom of the ring(s).
- Heteroaryl also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment to the parent molecular structure is either on the aryl or on the heteroaryl ring, or wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocycyl groups wherein the point of attachment to the parent molecular structure is on the heteroaryl ring.
- a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-10 membered heteroaryl”).
- a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-8 membered heteroaryl”).
- a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-6 membered heteroaryl”).
- the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur.
- the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur.
- heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4] oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzopyranonyl, benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl,
- a heteroaryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulf
- the invention is based on the unexpected discovery of novel, orally available, selective and potent inhibitors of mutated IDH 1 and/or IDH 2 proteins.
- the compounds disclosed here reversibly bind or form irreversible covalent bond with mutant IDH 1 and/or IDH 2 protein and effectively inhibit their respective alpha hydroxyl neoactivity.
- IDH inhibitors are currently being studied including 556 (WO2013046136A1), GSK321 and AG-221. These compounds reportedly bind to IDH1, IDH2, or both IDH1 and IDH2 in a reversible manner.
- the present invention provides a reversible or irreversible inhibition strategy that affords significant improved potency, selectivity and exposure time presumably due to the covalent bonding and a prolonged pharmacodynamics.
- the novel compounds disclosed herein some bear an electrophilic group that is suitable for reaction with IDH1, IDH2, or both IDH1 and IDH2 to form an irreversible covalent bond.
- the compounds bind to IDH1, IDH2, or both IDH1 and IDH2 in a non-covalent manner.
- Advantages of the approach disclosed herein include sustained target inhibition, which can be achieved with only transient exposure of the target to the inhibitor. This approach reduces the need to achieve pharmacological properties that would allow for sustained drug levels in vivo.
- the invention generally relates to a compound having the structure of formula (I):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- R E is a group comprising an electrophilic warhead
- R E comprises a group selected from:
- the compound has the structural formula (II):
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moieties and/or comprises an electrophilic warhead selected from:
- R 1 is H.
- R 1 is a halogen atom.
- R 2 is Q-R 6 wherein Q is CH 2 , NH or O, R 6 comprises a group selected from:
- R 2 is Q-R 6 , wherein Q is CH 2 , NH or O, and R 6 comprises a piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl or azetidinyl moiety and an electrophilic group.
- R 6 is selected from the group consisting of:
- R A is H
- R B is H
- Z 1 is CH and Z 2 is CH
- the compound has the structural formula (II-1):
- the compound is selected from the group consisting of:
- R A is H
- R B is H
- Z 1 is N
- Z 2 is N, having the structural formula (II-2):
- the compound is selected from the group consisting of:
- R A is H
- R B is H
- Z 1 is N
- Z 2 is CH
- the compound has the structural formula (II-3):
- X is S and Y is CH.
- X is O and Y is CH.
- X is NH and Y is CH.
- Z 1 and Z 2 is CH.
- Z 1 is N and Z 2 is CH.
- Z 1 is N and Z 2 is N.
- the compound is selected from the group consisting of:
- R 3 comprises a cyclic saturated or unsaturated group with a 5- to 7-member ring selected from piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moieties consisting of an electrophilic group.
- the compound is selected from the group consisting of:
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moiety and/or comprises of an electrophilic group selected from:
- R 1 is H.
- R 1 is a halogen atom.
- R 2 is Q-R 6 , wherein Q is CH 2 , NH or O, R 6 comprises a piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl or azetidinyl moiety and an electrophilic group selected from:
- R 6 is selected from the group consisting of:
- R A is H
- R B is H
- Z 1 is N
- Z 2 is CH
- R A is H
- R B is H
- Z 1 is N
- Z 2 is N, having structural formula (III-2):
- exemplary compounds of (III-1) include:
- exemplary compounds of (III-1) include:
- the invention generally relates to a pharmaceutical composition.
- the pharmaceutical composition includes a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent.
- the invention generally relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound having the structural formula of (I):
- each of R A and R B is independently H or a halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- R E is a group comprising an electrophilic warhead
- R E of the compound comprises a group selected from:
- the compound has the structural formula of (II):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively,
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the compound has the structural formula of (III):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively,
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- the invention generally relates to a method for treating, reducing, or preventing a disease or disorder.
- the method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- R E is a group comprising an electrophilic warhead
- the invention generally relates to a method for treating, reducing, or preventing a disease or disorder.
- the method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (II):
- each of R A and R B is independently H or a halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the invention generally relates to a method for treating, reducing, or preventing a disease or disorder.
- the method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (III):
- each of R A and R B is independently H or halogen, CN, CF 3 , alkylamine, alkoxy and alky group, or R A and R B join together to form a 5-membered aromatic ring along with the two carbons (—C ⁇ C—) of the pyrimidine ring that R A and R B are bonded to respectively;
- Z 1 and Z 2 is independently CH or N;
- R 1 is H or a halogen atom
- R 2 is a functional group that comprises an electrophilic group
- the one or more cancers comprise a blood cancer or a hematologic malignance.
- the one or more cancers are selected from B-acute lymphoblastic leukemias, B-acute lymphoblastic leukemias, chronic myelomonocytic leukemia, cute myelogenous leukemia, lymphoma, myelodysplasia syndrome, myeloproliferative neoplasms and myeloproliferative neoplasms.
- Any appropriate route of administration can be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intraventricular, intracorporeal, intraperitoneal, rectal, or oral administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the compounds described herein or derivatives thereof are admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or
- fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid
- binders as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia
- humectants as for example, glycerol
- disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate
- solution retarders as for example, paraffin
- absorption accelerators as for example, quaternary
- the dosage forms may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like.
- Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, such as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- the composition can also include additional agents,
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms.
- the present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention.
- Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
- the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- Benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) To a solution of benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) (0.45 g, 1 mmol) in EtOAc, was added 4N HCl/EtOAc (8 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 3 h. A saturated sodium bicarbonate solution was added to the solution and the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na 2 SO 4 ), and concentrated.
- Benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) To a solution of benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) (0.45 g, 1 mmol) in EtOAc (3 mL), was added 4N HCl/EtOAc (8 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 3 h.
- 5-bromo-2-(bromomethyl)pyrimidine (2) 5-bromo-2-methylpyrimidine (1) (1.73 g, 10 mmol) was dissolved in CCl 4 (17 mL) and treated with NBS (1.96 g, 11 mmol) and benzoylperoxide (0.48 g, 2 mmol). The reaction mixture was heated at 120° C. for 6 h. The reaction mixture was extracted with EtOAc and organic layers were washed with brine, dried over Na 2 SO 4 . Silica gel column chromatography provided 5-bromo-2-(bromomethyl)pyrimidine (2). MS m/z250 [M+H] + .
- Benzyl 4-((5-bromopyrimidin-2-yl)methyl)piperazine-1-carboxylate (4) To a solution of benzyl piperazine-1-carboxylate (3) (0.85 g, 3.86 mmol) in dry DCM (10 mL) was added TEA (0.65 g, 6.44 mmol). The resulting mixture was cooled to 0° C., and then 5-bromo-2-(bromomethyl)pyrimidine (2) (0.81 g, 3.22 mmol) was added and the solution was stirred for 30 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na 2 SO 4 ), and concentrated. Silica gel column chromatography provided benzyl 4-((5-bromopyrimidin-2-yl)methyl)piperazine-1-carboxylate (4). MS m/z391 [M+H]+.
- Benzyl 4-((5-acetylpyrimidin-2-yl)methyl)piperazine-1-carboxylate (6) PdCl 2 (PPh 3 ) 2 (77 mg, 0.11 mmol) was added to a solution of benzyl 4-((5-bromopyrimidin-2-yl)methyl)piperazine-1-carboxylate (4) (0.86 g, 2.2 mmol) and tributyl(1-ethoxyvinyl)stannane (5) (0.87 g, 2.42 mmol) in THF (12 mL). The solution was degassed and filled with nitrogen and then was heated at 70° C. for 12 h.
- reaction mixture was quenched with 2 M KF (10 mL) and extracted with EtOAc. The combined organic layers were washed with 2M KF, brine, dried over Na 2 SO 4 , and concentrated under vacuum to afford a yellow residue which was used in the next step without purification.
- Benzyl 4-((5-(1-aminoethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate(7) A 100 mL round-bottom flask was charged with a solution of benzyl 4-((5-acetylpyrimidin-2-yl)methyl)piperazine-1-carboxylate(6) (0.65 g, 1.83 mmol) in NH 3 /EtOH (30 mL), acetic acid (1.1 g, 18.3 mmol) and NaBH 3 CN (0.23 g, 3.66 mmol). The resulting solution was stirred at 90° C. for 3 h. The reaction progress was monitored by TLC.
- 6-chloronicotinoyl chloride (2) 6-chloronicotinic acid (1) (10 g, 63.5 mmol) was refluxed in thionylchloride (100 mL) under nitrogen for 3 h. volatiles were removed under reduced pressure.
- the toluene layer was separated and solvent was removed in vacuum to give a white needle-like solid.
- the solid was directly treated with DMSO (22 mL) and water (1 mL). The mixture was heated at 155° C. for 3 h and then it was cooled down to room temperature. It was then quenched with water, and the solid was collected by filtration. The solid was dissolved in DCM and dried over MgSO 4 and the solvent was removed under vacuum to give the product as a white solid.
- reaction mixture was quenched with 2 M KF (20 mL) and extracted with EtOAc. The combined organic layers were washed with 2M KF, brine, dried over Na 2 SO 4 , and concentrated under vacuum to afford a yellow residue which was used in the next step without purification.
- Benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) To a solution of benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) (0.45 g, 1 mmol) in EtOAc (3 mL), was added 4N HCl/EtOAc (8 mL) in an ice bath. The resulting mixture was stirred at room temperature for 3 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then the solution was extracted with EtOAc. Organic layers were dried, and concentrated.
- Assay Format The production or depletion of NADPH by IDH enzymes was measured by diaphorase/resazurin coupled detection.
- Subtract background (the average value of the No Enzyme control wells) from raw data. Average the DMSO control wells and set value as 100%. Take ratio of measured data/average DMSO control value times 100% to arrive at % activity.
Abstract
The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.
Description
- This application claims the benefit of priority from U.S. Provisional Application Ser. No. 62/436,328, filed on Dec. 19, 2016, and 62/536,367, filed Jul. 24, 2017, the entire content of each of which is incorporated herein by reference in its entirety.
- The invention generally relates to therapeutics and treatment methods for certain diseases and conditions. More particularly, the invention provides novel chemical compounds and pharmaceutical compositions thereof useful for treating cancer and methods of preparation and use thereof.
- Isocitrate dehydrogenase (IDH) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2. IDH exists in three isoforms in humans: IDH3 catalyzes the third step of the citric acid cycle while converting NAD+ to NADH in the mitochondria. The isoforms IDH1 and IDH2 catalyze the same reaction outside the context of the citric acid cycle and use NADP+ as a cofactor instead of NAD+. IDHs localize to the cytosol as well as the mitochondrion and peroxisome.
- Normal, wild type IDH enzymes help to break down nutrients and generate energy for cells. When mutated, IDH creates a molecule that alters the cells' genetic programming, and instead of maturing, the cells remain primitive and proliferate quickly. Non-mutant IDH 1/2 catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) thereby reducing NAD+(NADP+) to NADP (NADPH), e.g., in the forward reaction.
- IDH1 and IDH2 are mutated in a wide range of hematologic and solid tumor malignancies. Mutations of IDH 1/2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of -ketoglutarate to R (−)-2-hydroxyglutarate (2HG), which is not formed by wild-type IDH 1/2. Human IDH2 gene encodes a protein of 452 amino acids. (GenBank entries NM_002168.2 and NP 002159.2; The MGC Project Team 2004, Genome Res. 14:2121-2127). Human IDH1 gene encodes a protein of 414 amino acids (GenBank entries NM_005896.2 and NP 005887.2; Nekrutenko et al, 1998 Mol. Biol. Evol. 15:1674-1684; Geisbrecht et al, 1999 J. Biol. Chem. 274:30527-30533; Wiemann et al, 2001 Genome Res. 11:422-435; The MGC Project Team 2004 Genome Res. 14:2121-2127; Sjoeblom et al. 2006 Science 314:268-274.) 2HG production is believed to contribute to the formation and progression of cancer. (Dang, et al. 2009 Nature 462:739-44.)
- There is an urgent and growing need for improved cancer therapeutics and treatment methods, e.g., via effective inhibition of mutant IDH 1/2 and their alpha hydroxyl neoactivity.
- The invention provides novel, orally available, selective and potent inhibitors of mutated IDH 1 and/or IDH 2 proteins. The compounds disclosed here form irreversible covalent bond with mutant IDH 1 and/or IDH 2 protein and effectively inhibit their respective alpha hydroxyl activity.
- In one aspect, the invention generally relates to a compound having the structure of formula (I)
- wherein,
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- RE is a group comprising an electrophilic warhead,
- or a pharmaceutically acceptable form thereof.
- In certain embodiments of, RE comprises a group selected from:
- In certain embodiments, the compound has the structural formula (II):
- wherein,
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moieties and/or comprises an electrophilic warhead selected from:
- In certain embodiments of (I), having the structural formula (III)
- wherein
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moiety and/or comprises of an electrophilic group selected from:
- In another aspect, the invention generally relates to a pharmaceutical composition. The pharmaceutical composition includes a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent.
- In yet another aspect, the invention generally relates to a pharmaceutical composition comprising a compound having the structural formula of (I):
- wherein,
- each of RA and RB is independently H or a halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- RE is a group comprising an electrophilic warhead,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In certain embodiments of the pharmaceutical composition, RE of the compound comprises a group selected from:
- In yet another aspect, the invention generally relates to a pharmaceutical composition comprising a compound having the structural formula of (II):
- wherein,
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In yet another aspect, the invention generally relates to a pharmaceutical composition comprising a compound having the structural formula of (III):
- wherein,
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In yet another aspect, the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- In yet another aspect, the invention generally relates to a method for treating, reducing, or preventing a disease or disorder. The method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- wherein,
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- RE is a group comprising an electrophilic warhead,
- or a pharmaceutically acceptable form thereof, or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In another aspect, the invention generally relates to a method for treating, reducing, or preventing a disease or disorder. The method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (II):
- wherein,
- each of RA and RB is independently H or a halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In another aspect, the invention generally relates to a method for treating, reducing, or preventing a disease or disorder. The method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (III):
- wherein,
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
-
FIG. 1 shows exemplary Intact Mass spectrum of IDH1 R132C and labeled Mass Spectrum of IDH1 R132C treated with ISO1 and ISO3, respectively. -
FIG. 2 shows exemplary Intact Mass of IDH1 R132C. -
FIG. 3 shows exemplary Labeled Mass Spectrum of IDH1 R132C treated with ISO1. - Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. General principles of organic chemistry, as well as specific functional moieties and reactivity, are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 2006.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
- As used herein, “administration” of a disclosed compound encompasses the delivery to a subject of a compound as described herein, or a prodrug or other pharmaceutically acceptable derivative thereof, using any suitable formulation or route of administration, as discussed herein.
- As used herein, the term “electrophilic group” or “electrophile” refers to group or moiety that is attracted towards and capable of accepting a pair of electrons to form a new covalent bond. Exemplary electrophilic groups include an acrylamide group.
- As used herein, the terms “effective amount” or “therapeutically effective amount” refer to that amount of a compound or pharmaceutical composition described herein that is sufficient to effect the intended application including, but not limited to, disease treatment, as illustrated below. In some embodiments, the amount is that effective for detectable killing or inhibition of the growth or spread of cancer cells; the size or number of tumors; or other measure of the level, stage, progression or severity of the cancer. The therapeutically effective amount can vary depending upon the intended application, or the subject and disease condition being treated, e.g., the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the weight and age of the patient, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of cell migration. The specific dose will vary depending on, for example, the particular compounds chosen, the species of subject and their age/existing health conditions or risk for health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- As used herein, the terms “treatment” or “treating” a disease or disorder refers to a method of reducing, delaying or ameliorating such a condition before or after it has occurred. Treatment may be directed at one or more effects or symptoms of a disease and/or the underlying pathology. Treatment is aimed to obtain beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disorder. For prophylactic benefit, the pharmaceutical compounds and/or compositions can be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. The treatment can be any reduction and can be, but is not limited to, the complete ablation of the disease or the symptoms of the disease. As compared with an equivalent untreated control, such reduction or degree of prevention is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, or 100% as measured by any standard technique.
- As used herein, the term “therapeutic effect” refers to a therapeutic benefit and/or a prophylactic benefit as described herein. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- As used herein, the term “pharmaceutically acceptable ester” refers to esters that hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Such esters can act as a prodrug as defined herein. Pharmaceutically acceptable esters include, but are not limited to, alkyl, alkenyl, alkynyl, aryl, aralkyl, and cycloalkyl esters of acidic groups, including, but not limited to, carboxylic acids, phosphoric acids, phosphinic acids, sulfinic acids, sulfonic acids and boronic acids. Examples of esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates. The esters can be formed with a hydroxy or carboxylic acid group of the parent compound.
- As used herein, the term “pharmaceutically acceptable enol ethers” include, but are not limited to, derivatives of formula —C═C(OR) where R can be selected from alkyl, alkenyl, alkynyl, aryl, aralkyl and cycloalkyl. Pharmaceutically acceptable enol esters include, but are not limited to, derivatives of formula —C═C(OC(O)R) where R can be selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl and cycloalkyl.
- As used herein, a “pharmaceutically acceptable form” of a disclosed compound includes, but is not limited to, pharmaceutically acceptable salts, esters, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives of disclosed compounds. In one embodiment, a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, esters, isomers, prodrugs and isotopically labeled derivatives of disclosed compounds. In some embodiments, a “pharmaceutically acceptable form” includes, but is not limited to, pharmaceutically acceptable salts, esters, stereoisomers, prodrugs and isotopically labeled derivatives of disclosed compounds.
- In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt. As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchioric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoracetic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- The salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of a parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4 alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt can be chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
- In certain embodiments, the pharmaceutically acceptable form is a “solvate” (e.g., a hydrate). As used herein, the term “solvate” refers to compounds that further include a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. The solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. Where the solvent is water, the solvate is a “hydrate”. Pharmaceutically acceptable solvates and hydrates are complexes that, for example, can include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3 or about 4, solvent or water molecules. It will be understood that the term “compound” as used herein encompasses the compound and solvates of the compound, as well as mixtures thereof.
- In certain embodiments, the pharmaceutically acceptable form is a prodrug. As used herein, the term “prodrug” (or “pro-drug”) refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound. A prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood). In certain cases, a prodrug has improved physical and/or delivery properties over the parent compound. Prodrugs can increase the bioavailability of the compound when administered to a subject (e.g., by permitting enhanced absorption into the blood following oral administration) or which enhance delivery to a biological compartment of interest (e.g., the brain or lymphatic system) relative to the parent compound. Exemplary prodrugs include derivatives of a disclosed compound with enhanced aqueous solubility or active transport through the gut membrane, relative to the parent compound.
- The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein. Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it can enhance absorption from the digestive tract, or it can enhance drug stability for long-term storage.
- As used herein, the term “pharmaceutically acceptable” excipient, carrier, or diluent refers to a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymer as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- As used herein, the term “subject” refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment. Typically, the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.
- Compounds of the present invention are, subsequent to their preparation, preferably isolated and purified to obtain a composition containing an amount by weight equal to or greater than 95% (“substantially pure”), which is then used or formulated as described herein. In certain embodiments, the compounds of the present invention are more than 99% pure.
- Solvates and polymorphs of the compounds of the invention are also contemplated herein. Solvates of the compounds of the present invention include, for example, hydrates.
- Definitions of specific functional groups and chemical terms are described in more detail below. When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example “C1-6 alkyl” is intended to encompass, C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.
- As used herein, the term “alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., C1-10 alkyl). Whenever it appears herein, a numerical range such as “1 to 10” refers to each integer in the given range; e.g., “1 to 10 carbon atoms” means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, “alkyl” can be a C1-6 alkyl group. In some embodiments, alkyl groups have 1 to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while saturated branched alkyls include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like. The alkyl is attached to the parent molecule by a single bond. Unless stated otherwise in the specification, an alkyl group is optionally substituted by one or more of substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein. In a non-limiting embodiment, a substituted alkyl can be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl, and phenethyl.
- As used herein, the term “alkoxy” refers to the group —O-alkyl, including from 1 to 10 carbon atoms (C1-10) of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C1-3 alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 3 carbon atoms. Unless stated otherwise in the specification, an alkoxy group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein.
- As used herein, the terms “aromatic” or “aryl” refer to a radical with 6 to 14 ring atoms (e.g., C6-14 aromatic or C6-14 aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl). In some embodiments, the aryl is a C6-10 aryl group. For example, bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. In other embodiments, bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in“-yl” by removal of one hydrogen atom from the carbon atom with the free valence are named by adding “-idene” to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Whenever it appears herein, a numerical range such as “6 to 14 aryl” refers to each integer in the given range; e.g., “6 to 14 ring atoms” means that the aryl group can consist of 6 ring atoms, 7 ring atoms, etc., up to and including 14 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In a multi-ring group, only one ring is required to be aromatic, so groups such as indanyl are encompassed by the aryl definition. Non-limiting examples of aryl groups include phenyl, phenalenyl, naphthalenyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like. Unless stated otherwise in the specification, an aryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(=O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein.
- As used herein, the terms “cycloalkyl” and “carbocyclyl” each refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated. Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or “cycloalkynyl” if the carbocycle contains at least one triple bond. Cycloalkyl groups include groups having from 3 to 13 ring atoms (i.e., C3-13 cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 13 carbon atoms” means that the cycloalkyl group can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 13 carbon atoms. The term “cycloalkyl” also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In some embodiments, “cycloalkyl” can be a C3-8 cycloalkyl radical. In some embodiments, “cycloalkyl” can be a C3-5 cycloalkyl radical. Illustrative examples of cycloalkyl groups include, but are not limited to the following moieties: C3-6 carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6) and the like. Examples of C3-7 carbocyclyl groups include norbornyl (C7). Examples of C3-8 carbocyclyl groups include the aforementioned C3-7 carbocyclyl groups as well as cycloheptyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 carbocyclyl groups include the aforementioned C3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl and the like. Unless stated otherwise in the specification, a cycloalkyl group can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein. The terms “cycloalkenyl” and “cycloalkynyl” mirror the above description of “cycloalkyl” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl” or “alkynyl” terms are as described herein. For example, a cycloalkenyl group can have 3 to 13 ring atoms, such as 5 to 8 ring atoms. In some embodiments, a cycloalkynyl group can have 5 to 13 ring atoms.
- As used herein, the term “halide”, “halo”, or, alternatively, “halogen” means fluoro, chloro, bromo or iodo. The terms “haloalkyl,” “haloalkenyl,” “haloalkynyl” and “haloalkoxy” include alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof. For example, the terms “fluoroalkyl” and “fluoroalkoxy” include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like. Each of the alkyl, alkenyl, alkynyl and alkoxy groups are as defined herein and can be optionally further substituted as defined herein.
- As used herein, the term “heteroalkyl” refers to an alkyl radical, which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof. A numerical range can be given, e.g., C1-4 heteroalkyl which refers to the chain length in total, which in this example is 4 atoms long. For example, a —CH2OCH2CH3 radical is referred to as a “C4” heteroalkyl, which includes the heteroatom center in the atom chain length description. Connection to the parent molecular structure can be through either a heteroatom or a carbon in the heteroalkyl chain. For example, an N-containing heteroalkyl moiety refers to a group in which at least one of the skeletal atoms is a nitrogen atom. One or more heteroatom(s) in the heteroalkyl radical can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. For example, heteroalkyl also includes skeletal chains substituted with one or more nitrogen oxide (—O—) substituents. Exemplary heteroalkyl groups include, without limitation, ethers such as methoxyethanyl (—CH2CH2OCH3), ethoxymethanyl (—CH2OCH2CH3), (methoxymethoxy)ethanyl (—CH2CH2OCH2OCH3), (methoxymethoxy) methanyl (—CH2OCH2OCH3) and (methoxyethoxy)methanyl (—CH2OCH2CH2OCH3) and the like; amines such as (—CH2CH2NHCH3, —CH2CH2N(CH3)2, —CH2NHCH2CH3, —CH2N(CH2CH3)(CH3)) and the like.
- As used herein, the term “heteroaryl” or, alternatively, “heteroaromatic” refers to a refers to a radical of a 5-18 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic and the like) aromatic ring system (e.g., having 6, 10 or 14 π electrons shared in a cyclic array) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur (“5-18 membered heteroaryl”). Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. Whenever it appears herein, a numerical range such as “5 to 18” refers to each integer in the given range; e.g., “5 to 18 ring atoms” means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some instances, a heteroaryl can have 5 to 14 ring atoms. In some embodiments, the heteroaryl has, for example, bivalent radicals derived from univalent heteroaryl radicals whose names end in “-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding “-ene” to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylene.
- For example, an N-containing “heteroaromatic” or “heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. One or more heteroatom(s) in the heteroaryl radical can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (—O—) substituents, such as pyridinyl N-oxides. The heteroaryl is attached to the parent molecular structure through any atom of the ring(s).
- “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment to the parent molecular structure is either on the aryl or on the heteroaryl ring, or wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocycyl groups wherein the point of attachment to the parent molecular structure is on the heteroaryl ring. For polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl and the like), the point of attachment to the parent molecular structure can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur.
- Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4] oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzopyranonyl, benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno [2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furo [3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d] pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo [4,5 ]thieno [2,3-d]pyrimdinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno [2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno [2,3-c]pridinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise in the specification, a heteroaryl moiety can be optionally substituted by one or more substituents which independently include: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo, haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, —Si(Ra)3, —ORa, —SRa, —OC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), —P(═O)(Ra)(Ra), or —O—P(═O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, and each of these moieties can be optionally substituted as defined herein.
- The invention is based on the unexpected discovery of novel, orally available, selective and potent inhibitors of mutated IDH 1 and/or IDH 2 proteins. The compounds disclosed here reversibly bind or form irreversible covalent bond with mutant IDH 1 and/or IDH 2 protein and effectively inhibit their respective alpha hydroxyl neoactivity.
- Several IDH inhibitors are currently being studied including 556 (WO2013046136A1), GSK321 and AG-221. These compounds reportedly bind to IDH1, IDH2, or both IDH1 and IDH2 in a reversible manner.
- The reported reversible inhibitors have shown less than optimal potency, selectivity and exposure time.
- In contrast, the present invention provides a reversible or irreversible inhibition strategy that affords significant improved potency, selectivity and exposure time presumably due to the covalent bonding and a prolonged pharmacodynamics.
- Among the novel compounds disclosed herein, some bear an electrophilic group that is suitable for reaction with IDH1, IDH2, or both IDH1 and IDH2 to form an irreversible covalent bond. For the reversible inhibitors of the invention, the compounds bind to IDH1, IDH2, or both IDH1 and IDH2 in a non-covalent manner.
- Advantages of the approach disclosed herein include sustained target inhibition, which can be achieved with only transient exposure of the target to the inhibitor. This approach reduces the need to achieve pharmacological properties that would allow for sustained drug levels in vivo.
- In one aspect, the invention generally relates to a compound having the structure of formula (I):
- wherein,
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- RE is a group comprising an electrophilic warhead,
- or a pharmaceutically acceptable form thereof.
- In certain embodiments of, RE comprises a group selected from:
- In certain embodiments of (I), the compound has the structural formula (II):
- wherein,
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moieties and/or comprises an electrophilic warhead selected from:
- In certain embodiments, R1 is H.
- In certain embodiments, R1 is a halogen atom.
- In certain embodiments, R2 is Q-R6 wherein Q is CH2, NH or O, R6 comprises a group selected from:
- In certain embodiments, R2 is Q-R6, wherein Q is CH2, NH or O, and R6 comprises a piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl or azetidinyl moiety and an electrophilic group.
- In certain embodiments, R6 is selected from the group consisting of:
- In certain embodiments of (I), RA is H, RB is H, Z1 is CH and Z2 is CH, and the compound has the structural formula (II-1):
- In certain embodiments, the compound is selected from the group consisting of:
- In certain embodiments of (I), RA is H, RB is H, Z1 is N and Z2 is N, having the structural formula (II-2):
- In certain embodiments, the compound is selected from the group consisting of:
- In certain embodiments of (I), RA is H, RB is H, Z1 is N and Z2 is CH, and the compound has the structural formula (II-3):
- In certain embodiments of (I), RA and RB together is —Y=CH—X—, wherein, X is S, O or NH and Y is CH or N, having the structural formula (II-4):
- In certain embodiments, X is S and Y is CH.
- In certain embodiments, X is O and Y is CH.
- In certain embodiments, X is NH and Y is CH.
- In certain embodiments, Z1 and Z2 is CH.
- In certain embodiments, Z1 is N and Z2 is CH.
- In certain embodiments, Z1 is N and Z2 is N.
- In certain embodiments, the compound is selected from the group consisting of:
- wherein R3 comprises a cyclic saturated or unsaturated group with a 5- to 7-member ring selected from piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moieties consisting of an electrophilic group.
- In certain embodiments, the compound is selected from the group consisting of:
- In certain embodiments of (I), having the structural formula (III)
- wherein
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 comprises a group selected from: piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl and azetidinyl moiety and/or comprises of an electrophilic group selected from:
- In certain embodiments, R1 is H.
- In certain embodiments, R1 is a halogen atom.
- In certain embodiments, R2 is Q-R6, wherein Q is CH2, NH or O, R6 comprises a piperidinyl, piperazinyl, phenyl, pyridinyl, pyrrolyl or azetidinyl moiety and an electrophilic group selected from:
- In certain embodiments, R6 is selected from the group consisting of:
- In certain embodiments of (III), RA is H, RB is H, Z1 is N, Z2 is CH, having structural formula (III-1):
- In certain embodiments of (III), RA is H, RB is H, Z1 is N, Z2 is N, having structural formula (III-2):
- In certain embodiments, exemplary compounds of (III-1) include:
- In certain embodiments, exemplary compounds of (III-1) include:
- In another aspect, the invention generally relates to a pharmaceutical composition. The pharmaceutical composition includes a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, or diluent.
- In another aspect, the invention generally relates to a pharmaceutical composition comprising a compound having the structural formula of (I):
- wherein,
- each of RA and RB is independently H or a halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- RE is a group comprising an electrophilic warhead,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In certain embodiments of the pharmaceutical composition, RE of the compound comprises a group selected from:
- In certain embodiments of the pharmaceutical composition, the compound has the structural formula of (II):
- wherein,
each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively, - Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In certain embodiments of the pharmaceutical composition, the compound has the structural formula of (III):
- wherein,
each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively, - Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In yet another aspect, the invention generally relates to a unit dosage form comprising a pharmaceutical composition disclosed herein.
- In yet another aspect, the invention generally relates to a method for treating, reducing, or preventing a disease or disorder. The method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
- wherein,
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- RE is a group comprising an electrophilic warhead,
- or a pharmaceutically acceptable form thereof, or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In another aspect, the invention generally relates to a method for treating, reducing, or preventing a disease or disorder. The method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (II):
- wherein,
- each of RA and RB is independently H or a halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In another aspect, the invention generally relates to a method for treating, reducing, or preventing a disease or disorder. The method includes: administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (III):
- wherein,
- each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
- Z1 and Z2 is independently CH or N;
- R1 is H or a halogen atom; and
- R2 is a functional group that comprises an electrophilic group,
- or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
- In certain embodiments of the methods, the one or more cancers comprise a blood cancer or a hematologic malignance.
- In certain embodiments of the methods, the one or more cancers are selected from B-acute lymphoblastic leukemias, B-acute lymphoblastic leukemias, chronic myelomonocytic leukemia, cute myelogenous leukemia, lymphoma, myelodysplasia syndrome, myeloproliferative neoplasms and myeloproliferative neoplasms.
- Any appropriate route of administration can be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intraventricular, intracorporeal, intraperitoneal, rectal, or oral administration. Most suitable means of administration for a particular patient will depend on the nature and severity of the disease or condition being treated or the nature of the therapy being used and on the nature of the active compound.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds described herein or derivatives thereof are admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (i) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (ii) binders, as for example, carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (iii) humectants, as for example, glycerol, (iv) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate, (v) solution retarders, as for example, paraffin, (vi) absorption accelerators, as for example, quaternary ammonium compounds, (vii) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, (viii) adsorbents, as for example, kaolin and bentonite, and (ix) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols, and the like. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others known in the art.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, such as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, and fatty acid esters of sorbitan, or mixtures of these substances, and the like. Besides such inert diluents, the composition can also include additional agents, such as wetting, emulsifying, suspending, sweetening, flavoring, or perfuming agents.
- Materials, compositions, and components disclosed herein can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed methods and compositions. It is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a method is disclosed and discussed and a number of modifications that can be made to a number of molecules including in the method are discussed, each and every combination and permutation of the method, and the modifications that are possible are specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed. This concept applies to all aspects of this disclosure including, but not limited to, steps in methods using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, it is understood that each of these additional steps can be performed with any specific method steps or combination of method steps of the disclosed methods, and that each such combination or subset of combinations is specifically contemplated and should be considered disclosed.
- Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
- Isomeric mixtures containing any of a variety of isomer ratios may be utilized in accordance with the present invention. For example, where only two isomers are combined, mixtures containing 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1, or 100:0 isomer ratios are contemplated by the present invention. Those of ordinary skill in the art will readily appreciate that analogous ratios are contemplated for more complex isomer mixtures.
- If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic methods well known in the art, and subsequent recovery of the pure enantiomers.
-
- Methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate(2) To a solution of methyl (S)-4-(1-aminoethyl)benzoate (1) (4.9 g, 22.7 mmol) in DCM (120 mL) was added di-tert-butyl dicarbonate (5.95 g, 27.3 mmol) and TEA (6.97 ml, 50 mmol). The solution was stirred for 7 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) as a white solid (6.2 g, 97.6%).
- Tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate(3) To a cooled (0° C.) solution of methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) (7.89 g, 28.2 mmol) in THF (142 mL) was added a solution of LiAlH4 (1.3 g, 33.84 mmol) in THF (17 mL) and the resulting mixture was stirred at room temperature for 30 min. The reaction mixture was quenched by addition of a 1N NaOH solution until gas evolution ceased. The reaction mixture was filtered, washed with EtOAc. After separation, the aqueous phase was washed with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) as a white solid (5.6 g, 79%). MS m/z178.08 [M−74+H]+.
- Tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate(4) To a solution of tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) (2.5 g, 10 mmol) in DCM (50 mL) was added methanesulfonyl chloride (1.4 g, 12 mmol) and TEA (2.02 g, 20 mmol). The solution was stirred for 12 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) as a white solid (1.28 g, 47.4%). MS m/z196.1 [M−74+H]+.
- Benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate(6) To a solution of tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) (1.28 g, 4.74 mmol) in DMF (6 mL) was added benzyl piperazine-1-carboxylate (1.15 g, 5.22 mmol) and K2CO3 (1.97 g, 14.22 mmol). The resulting mixture was heated at 80° C. for 3 h. Then it was extracted with EtOAc at room temperature and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) as a white solid (0.92 g, 42.8%). MS m/z454.26 [M+H]+.
- Benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) To a solution of benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) (0.45 g, 1 mmol) in EtOAc, was added 4N HCl/EtOAc (8 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 3 h. A saturated sodium bicarbonate solution was added to the solution and the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) as a white solid (0.34 g, 97%). MS m/z354.21 [M+H]+.
- (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one(8) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichloropyrimidine (b) (6.1 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2 atmosphere. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added to the solution. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) as a white solid (4 g, 40.4%). MS m/z242.09 [M+H]+.
- Benzyl 4-(4-4S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl) amino)ethyl)benzyl)piperazine-1-carboxylate (9) A solution of benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) (1.1 g, 3.11 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.83 g, 3.42 mmol) in DMSO (5 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc which was washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate (9) as a white solid (0.67 g, 38.5%). MS m/z559.29[M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) A mixture of Benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate (9) (0.67 g, 1.2 mmol) and 10% Pd—C (0.1 g) in ethanol (5 mL) is stirred under hydrogen for overnight. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as a white solid (0.42 g, 82%). MS m/z213.13/425.26[M+H]+.
- (S)-3-(2-(((S)-1-(4-((4-acryloylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO1) To a solution of (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.1 mg, 0.24 mmol) in dry acetonitrile (3 mL) was added DIEA (62 mg, 0.48 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (21.7 mg, 0.24 mmol) was added the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((4-acryloylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO1) as a white solid (46 mg, 40%). MS m/z240.14/479.28[M+H]+. 1H NMR (400 MHz, DMSO) δ 8.16 (d, J=5.1 Hz, 1H), 7.78 (s, 1H), 7.27 (d, J=7.2 Hz, 2H), 7.23-7.14 (m, 3H), 6.76 (dd, J=16.7, 10.5 Hz, 1H), 6.13-6.02 (m, 1H), 5.65 (dd, J=10.4, 2.4 Hz, 1H), 4.97 (s, 1H), 4.61 (s, 1H), 4.33 (dd, J=18.0, 9.7 Hz, 2H), 3.51 (s, 4H), 3.40 (d, J=29.6 Hz, 2H), 2.31 (s, 4H), 1.75 (s, 1H), 1.39 (t, J=17.0 Hz, 3H), 0.69 (dd, J=97.7, 44.6 Hz, 6H).
-
- Methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) To a solution of methyl (S)-4-(1-aminoethyl)benzoate (1) (4.9 g, 22.7 mmol) in DCM (120 mL) was added di-tert-butyl dicarbonate (5.95 g, 27.3 mmol) and TEA (6.97 mL, 50 mmol). The solution was stirred for 7 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) as a white solid (6.2 g, 97.6%).
- Tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) To a cooled (0° C.) solution of methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) (7.89 g, 28.2 mmol) in THF (142 mL) was added a solution of LiAlH4 (1.3 g, 33.84 mmol) in THF (17 mL) and the resulting mixture was stirred at room temperature for 30 min. The reaction mixture was quenched by addition of a 1N NaOH solution until gas evolution ceased. The reaction mixture was filtered, washed with EtOAc. After separation, the aqueous phase was washed with EtOAc. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) as a white solid (5.6 g, 79%). MS m/z178 [M−74+H]+.
- Tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) To a solution of tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) (2.5 g, 10 mmol) in DCM (50 mL) was added methanesulfonyl chloride (1.4 g, 12 mmol) and TEA (2.02 g, 20 mmol). The solution was stirred for 12 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) as a white solid (1.28 g, 47.4%). MS m/z196 [M−74+H]+.
- Benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) To a solution of tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) (1.28 g, 4.74 mmol) in DMF (6 mL) was added benzyl piperazine-1-carboxylate (1.15 g, 5.22 mmol) and K2CO3 (1.97 g, 14.22 mmol). The resulting mixture was heated at 80° C. for 3 h. Then it was extracted with EtOAc and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) as a white solid (0.92 g, 42.8%). MS m/z454 [M+H]+.
- Benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) To a solution of benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) (0.45 g, 1 mmol) in EtOAc (3 mL), was added 4N HCl/EtOAc (8 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 3 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) as a white solid (0.34 g, 97%). MS m/z354 [M+H]+.
- (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichloropyrimidine (b) (6.1 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2 atmosphere. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine and then was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) as a white solid (4 g, 40.4%). MS m/z242 [M+H]+.
- Benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl) amino)ethyl)benzyl)piperazine-1-carboxylate (9) A solution of benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) (1.1 g, 3.11 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.83 g, 3.42 mmol) in DMSO (5 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate (9) as a white solid (0.67 g, 38.5%). MS m/z559[M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) A mixture of Benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate (9) (0.67 g, 1.2 mmol) and 10% Pd—C (0.1 g) in ethanol (5 mL) is stirred under hydrogen for overnight. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as a white solid (0.42 g, 82%). MS m/z213/425[M+H]+.
- (S)-3-(2-(((S)-1-(4-((4-((E)-4-(dimethylamino)but-2-enoyl)piperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO2) To a solution of (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.21 g, 0.49 mmol) in dry acetonitrile (5 mL) was added DIEA (96 mg, 0.74 mmol). The resulting mixture was cooled down to −20° C. and then (E)-4-bromobut-2-enoyl chloride (0.13 g, 0.74 mmol) was added and the solution was stirred for 5 min. And then 2M dimethylamine solution in THF was added, and the resulting mixture was stirred at room temperature for 3 h. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((4-((E)-4-(dimethylamino)but-2-enoyl)piperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO2) as a white solid (50 mg, 15%). MS m/z536[M+H]+. 1H NMR (400 MHz, DMSO) δ 8.20-8.10 (m, 1H), 7.80 (s, 1H), 7.35-7.25 (m, 2H), 7.25-7.15 (m, 3H), 6.85-6.77 (m, 1H), 6.66-6.56 (m, 1H), 4.97 (s, 1H), 4.61 (s, 1H), 4.41-4.22 (m, 2H), 3.66-3.43 (m, 8H), 2.59-2.51 (m, 4H), 2.41-2.24 (m, 4H), 1.74 (s, 1H), 1.41 (d, J=7.0 Hz, 3H), 0.78-0.35 (m, 6H).
-
- (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) To a solution of (S)-1-(4-bromophenyl)ethan-1-amine (1) (2 g, 10 mmol) in DCM (20 mL) was added di-tert-butyl dicarbonate (2.4 g, 11 mmol) and TEA (1.27 g, 12.4 mmol). The solution was stirred for 3 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) as a white solid (2.9 g, 96.7%).
- Tert-butyl (S)-(1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)carbamate (4) The 5-nitropyridin-2-amine(3) (1.38 g, 9.9 mmol), CuI (0.86 g, 4.5 mmol) and anhydrous K2CO3 (2.49 g, 18 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and filled with nitrogen gas three times. A solution of (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) (2.69 g, 9 mmol) and DMEDA (0.4 g, 4.5 mmol) 1,4-dioxane (45 ml) was added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. And a saturated solution of NaCl was added the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided Tert-butyl (S)-(1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)carbamate (4) as a yellow solid (1.48 g, 46%).
- (S)—N-(4-(1-aminoethyl)phenyl)-5-nitropyridin-2-amine (5) To a solution of tert-butyl (S)-(1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)carbamate (4) (2.52 g, 7.03 mmol) in EtOAc (5 mL), was added 4N HCl/EtOAc (10 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 1.5 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)—N-(4-(1-aminoethyl)phenyl)-5-nitropyridin-2-amine (5) as a yellow solid (1.67 g, 92%).
- (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichloropyrimidine (b) (6.1 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) as a white solid (4 g, 40.4%). MS m/z242.09 [M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-((5-nitropyridin-2-yl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (7) A solution of (S)—N-(4-(1-aminoethyl)phenyl)-5-nitropyridin-2-amine (5) (0.39 g, 1.5 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) (0.4 g, 1.65 mmol) in DMSO (3 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (7) as a solid (0.25 g, 36%). MS m/z217.61/464.2 [M+H]+.
- (S)-3-(2-(((S)-1-((5-aminopyridin-2-yl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A mixture of (S)-4-isopropyl-3-(2-(((S)-1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (7) (0.25 g, 0.54 mmol) and 10% Pd—C (0.1 g) in MeOH (5 mL) is stirred under hydrogen for 2 h. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((5-aminopyridin-2-yl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.175 g, 75%). MS m/z217.61/434.22[M+H]+.
- N-(6-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)pyridin-3-yl)acrylamide (ISO3) To a solution of (S)-3-(2-(((S)-1-(4-((5-aminopyridin-2-yl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (60 mg, 0.14 mmol) in dry acetonitrile (2 mL) was added DIEA (36 mg, 0.28 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (12.7 mg, 0.14 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (ISO3) as a solid (28 mg, 41%). MS m/z244.62/488.23[M+H]+. 1H NMR (400 MHz, DMSO) δ 10.03 (s, 1H), 8.86 (s, 1H), 8.37 (d, J=2.5 Hz, 1H), 8.16 (d, J=5.6 Hz, 1H), 7.83 (dd, J=8.9, 2.6 Hz, 1H), 7.68 (s, 1H), 7.48 (t, J=11.9 Hz, 2H), 7.24-7.16 (m, 3H), 6.79 (d, J=8.9 Hz, 1H), 6.46-6.34 (m, 1H), 6.23 (dd, J=17.0, 2.0 Hz, 1H), 5.72 (dt, J=11.9, 5.9 Hz, 1H), 4.94 (s, 1H), 4.69-4.60 (m, 1H), 4.34 (dd, J=17.7, 9.1 Hz, 2H), 2.00 (dd, J=16.4, 7.2 Hz, 1H), 1.42 (d, J=7.0 Hz, 3H), 0.65 (d, J=91.7 Hz, 6H).
-
- (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) To a solution of (S)-1-(4-bromophenyl)ethan-1-amine (1) (2 g, 10 mmol) in DCM (20 mL) was added di-tert-butyl dicarbonate (2.4 g, 11 mmol) and TEA (1.27 g, 12.4 mmol). The solution was stirred for 3 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) as a white solid (2.9 g, 96.7%).
- Tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate(4) The 4-nitroaniline (3) (1.01 g, 7.34 mmol), CuI (1.27 g, 6.67 mmol) and anhydrous K2CO3 (1.84 g. 13.34 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and back filled with nitrogen gas three times. A solution of (5)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) (2 g, 6.67 mmol) and DMEDA (0.59 g, 6.67 mmol) in 1,4-dioxane (30 mL) was added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. And a saturated solution of NaCl was added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided Tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate (4) as a yellow solid (1.2 g, 50.4%).
- (S)-4-(1-aminoethyl)-N-(4-nitrophenyl)aniline (5) To a solution of tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate (4) (1.2 g, 3.36 mmol) in EtOAc (5 mL) was added 4N HCl/EtOAc (10 mL) in an ice bath. The resulting mixture was stirred at room temperature for 3 h and saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried, and concentrated. Silica gel column chromatography provided (S)-4-(1-aminoethyl)-N-(4-nitrophenyl)aniline (5) as a yellow solid (0.8 g, 93%).
- (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichloropyrimidine (b) (6.1 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2 atmosphere. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) as a white solid (4 g, 40.4%). MS m/z242.09 [M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-((4-nitrophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (7) A solution of (S)-4-(1-aminoethyl)-N-(4-nitrophenyl)aniline (5) (0.24 g, 0.93 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) (0.25 g, 1.02 mmol) in DMSO (4 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-((4-nitrophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (7) as a yellow solid (0.26 g, 60.5%). MS m/z463.205[M+H]+.
- (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A mixture of (S)-4-isopropyl-3-(2-(((S)-1-(4-((4-nitrophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (7) (0.16 g, 0.346 mmol) and 10% Pd—C(50 mg) in MeOH (2 mL) is stirred under hydrogen for 2 h. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) as a solid (0.13 g, 86.7%). MS m/z433.23/217.12 [M+H]+.
- N-(4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)acrylamide (ISO4) To a solution of (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (80 mg, 0.185 mmol) in dry acetonitrile (3 mL) was added DIEA (48 mg, 0.37 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (16.7 mg, 0.185 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided N-(4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)acrylamide (ISO4) as a solid (30 mg, 33.3%). MS m/z487.24[M+H]+. 1H NMR (400 MHz, DMSO) δ 9.94 (s, 1H), 8.16 (d, J=5.6 Hz, 1H), 7.95 (s, 1H), 7.70 (s, 1H), 7.47 (dd, J=30.3, 8.6 Hz, 2H), 7.19 (t, J=6.9 Hz, 3H), 6.96 (dd, J=10.9, 8.7 Hz, 4H), 6.40 (dd, J=17.0, 10.1 Hz, 1H), 6.26-6.12 (m, 1H), 5.69 (dd, J=10.1, 2.1 Hz, 1H), 4.92 (s, 1H), 4.72-4.57 (m, 1H), 4.45-4.18 (m, 2H), 1.95 (d, J=31.0 Hz, 1H), 1.41 (d, J=7.0 Hz, 3H), 0.76 (s, 6H).
-
- (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (2) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichloropyrimidine (b) (6.1 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2 atmosphere. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (2) as a white solid (4 g, 40.4%). MS m/z242 [M+H]+.
- (S)-3-(2-(((S)-1-(4-bromophenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) A solution of (S)-1-(4-bromophenyl)ethan-1-amine (1) (4 g, 20 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (2) (5.3 g, 22 mmol) in DMSO (10 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-bromophenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) as a solid (4.2 g, 52%). MS m/z405 [M+H]+.
- Tert-butyl (3-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)carbamate (5) The (S)-3-(2-(((S)-1-(4-bromophenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) (1.01 g, 2.5 mmol), CuI (0.48 g, 2.5 mmol) and anhydrous K2CO3 (0.69 g. 2 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and back filled with nitrogen gas three times. A solution of tert-butyl (3-aminophenyl)carbamate (4) (1.04 g, 5 mmol) and DMEDA (0.22 g, 2.5 mmol) in 1,4-dioxane (12 mL) was added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. A saturated solution of NaCl was added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (3-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)carbamate (5) (0.3 g, 23%). MS m/z533 [M+H]+.
- (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) To a solution of tert-butyl (3-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)carbamate (5) (0.3 g, 0.56 mmol) in EtOAc (1 mL), was added 4N HCl/EtOAc (2 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 1 h. The saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then the solution was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) as a solid (0.2 g, 83%). MS m/z433 [M+H]+.
- N-(3-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)acrylamide (ISO5) To a solution of (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) (0.1 g, 0.21 mmol) in dry acetonitrile (2 mL) was added DIEA (81.4 mg, 0.63 mmol). The resulting mixture was cooled to −20° C. and then acryloyl chloride (19.3 mg, 0.21 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided N-(3-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)acrylamide (ISO5) as a solid (35 mg, 34%). MS m/z487 [M+H]+. 1H NMR (400 MHz, DMSO) δ 9.96 (s, 1H), 8.16 (d, J=5.6 Hz, 1H), 8.08 (s, 1H), 7.70 (s, 1H), 7.50 (s, 1H), 7.29-7.15 (m, 3H), 7.15-7.08 (m, 1H), 7.07-6.94 (m, 2H), 6.69 (d, J=9.0 Hz, 1H), 6.41 (dd, J=17.0, 10.1 Hz, 1H), 6.22 (dd, J=17.0, 2.1 Hz, 1H), 5.80-5.61 (m, 1H), 4.94 (s, 1H), 4.71-4.52 (m, 1H), 4.35 (dd, J=16.8, 8.7 Hz, 2H), 2.10-1.82 (m, 1H), 1.42 (d, J=7.0 Hz, 3H), 1.28-1.21 (m, 1H), 0.92-0.69 (m, 3H), 0.68-0.42 (m, 3H).
-
- 5-bromo-2-(bromomethyl)pyrimidine (2) 5-bromo-2-methylpyrimidine (1) (1.73 g, 10 mmol) was dissolved in CCl4 (17 mL) and treated with NBS (1.96 g, 11 mmol) and benzoylperoxide (0.48 g, 2 mmol). The reaction mixture was heated at 120° C. for 6 h. The reaction mixture was extracted with EtOAc and organic layers were washed with brine, dried over Na2SO4. Silica gel column chromatography provided 5-bromo-2-(bromomethyl)pyrimidine (2). MS m/z250 [M+H]+.
- Benzyl 4-((5-bromopyrimidin-2-yl)methyl)piperazine-1-carboxylate (4) To a solution of benzyl piperazine-1-carboxylate (3) (0.85 g, 3.86 mmol) in dry DCM (10 mL) was added TEA (0.65 g, 6.44 mmol). The resulting mixture was cooled to 0° C., and then 5-bromo-2-(bromomethyl)pyrimidine (2) (0.81 g, 3.22 mmol) was added and the solution was stirred for 30 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided benzyl 4-((5-bromopyrimidin-2-yl)methyl)piperazine-1-carboxylate (4). MS m/z391 [M+H]+.
- Benzyl 4-((5-acetylpyrimidin-2-yl)methyl)piperazine-1-carboxylate (6) PdCl2(PPh3)2 (77 mg, 0.11 mmol) was added to a solution of benzyl 4-((5-bromopyrimidin-2-yl)methyl)piperazine-1-carboxylate (4) (0.86 g, 2.2 mmol) and tributyl(1-ethoxyvinyl)stannane (5) (0.87 g, 2.42 mmol) in THF (12 mL). The solution was degassed and filled with nitrogen and then was heated at 70° C. for 12 h. The reaction mixture was quenched with 2 M KF (10 mL) and extracted with EtOAc. The combined organic layers were washed with 2M KF, brine, dried over Na2SO4, and concentrated under vacuum to afford a yellow residue which was used in the next step without purification.
- The above crude (2.2 mmol) was diluted with MeOH (6 mL) and 1M HCl (2 mL) added. The resulting yellow solution was stirred at room temperature for 2 h, and then the organic solvent was removed under reduced pressure. The residue was diluted with water, neutralized with 1N NaOH and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4. Silica gel column chromatography provided benzyl 4-((5-acetylpyrimidin-2-yl)methyl)piperazine-1-carboxylate (6). MS m/z355 [M+H]+.
- Benzyl 4-((5-(1-aminoethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate(7) A 100 mL round-bottom flask was charged with a solution of benzyl 4-((5-acetylpyrimidin-2-yl)methyl)piperazine-1-carboxylate(6) (0.65 g, 1.83 mmol) in NH3/EtOH (30 mL), acetic acid (1.1 g, 18.3 mmol) and NaBH3CN (0.23 g, 3.66 mmol). The resulting solution was stirred at 90° C. for 3 h. The reaction progress was monitored by TLC. The pH was adjusted to 8 with NaOH/H2O (3 mol/L). The resulting solution was extracted with DCM. Combined organic layers were dried over Na2SO4. Silica gel column chromatography provided benzyl 4-((5-(1-aminoethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (7). MS m/z356 [M+H]+.
- Benzyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (9) A solution of benzyl 4-((5-(1-aminoethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (7) (0.65 g, 1.83 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.53 g, 2.2 mmol) in DMSO (4 mL) was heated at 110° C. for 2 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided benzyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (9) as a solid. MS m/z561[M+H]+.
- (4S)-4-isopropyl-3-(2-((1-(2-(piperazin-1-ylmethyl)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) A mixture of benzyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-2-yl)methyl)piperazine-1-carboxylate (9) (0.36 g, 0.64 mmol) and 10% Pd—C(50 mg) in ethanol (5 mL) is stirred under hydrogen for overnight. The mixture is filtered and concentrated. Silica gel column chromatography provided (4S)-4-isopropyl-3-(2-((1-(2-(piperazin-1-ylmethyl)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as a white solid (0.42 g, 82%). MS m/z427[M+H]+.
- (4S)-3-(2-((1-(2-((4-acryloylpiperazin-1-yl)methyl)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO6) To a solution of (45)-4-isopropyl-3-(2-((1-(2-(piperazin-1-ylmethyl)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.12 g, 0.28 mmol) in dry acetonitrile (3 mL) was added DIEA (73 mg, 0.56 mmol). The resulting mixture was dropped to −20° C. and acryloyl chloride (31 mg, 0.34 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (4S)-3-(2-((1-(2-((4-acryloylpiperazin-1-yl)methyl)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one which was further purified by prep-TLC to obtain pure isomer as a white solid. (52 mg, 36%). MS m/z481 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.74 (d, J=6.8 Hz, 2H), 8.19 (s, 1H), 7.94 (s, 1H), 7.28 (d, J=18.9 Hz, 1H), 6.88-6.65 (m, 1H), 6.09 (d, J=16.6 Hz, 1H), 5.66 (d, J=10.1 Hz, 1H), 4.99 (d, J=57.6 Hz, 1H), 4.73-4.54 (m, 1H), 4.42-4.17 (m, 2H), 3.82-3.62 (m, 2H), 3.61-3.42 (m, 4H), 1.76-1.58 (m, 1H), 1.54-1.43 (m, 3H), 1.29-1.22 (m, 2H), 0.91 (d, J=6.8 Hz, 2H), 0.84 (d, J=6.5 Hz, 3H), 0.76 (d, J=6.1 Hz, 3H).
-
- 6-chloronicotinoyl chloride (2) 6-chloronicotinic acid (1) (10 g, 63.5 mmol) was refluxed in thionylchloride (100 mL) under nitrogen for 3 h. volatiles were removed under reduced pressure.
- 1-(6-chloropyridin-3-yl)ethan-1-one (4) To a solution of 250 mL three-neck round-bottom flask with mechanical stirring containing magnesium chloride (1.7 g, 17.5 mmol) in dry toluene 25 mL was added triethylamine (6.1 g, 60 mmol) and by dimethyl malonate (3) (4 g, 30 mmol). The resulting mixture was stirred at 25° C. for 1.5 h and then 6-chioronicotinic acid chloride (2) (4.4 g, 25 mmol) was added in the solid form slowly in small portions over 45 min. Stirring was continued for 40 min before concentrated HCl (7.6 g, 77.5 mmol) was carefully added to quench the reaction. The toluene layer was separated and solvent was removed in vacuum to give a white needle-like solid. The solid was directly treated with DMSO (22 mL) and water (1 mL). The mixture was heated at 155° C. for 3 h and then it was cooled down to room temperature. It was then quenched with water, and the solid was collected by filtration. The solid was dissolved in DCM and dried over MgSO4 and the solvent was removed under vacuum to give the product as a white solid.
- Tert-butyl 4-((5-acetylpyridin-2-yl)oxy)piperidine-1-carboxylate (6) Tert-butyl 4-hydroxypiperidine-1-carboxylate (5) (1.4 g, 6.94 mmol) was added to a DMF suspension (10 mL) of 60% sodium hydride (0.25 g, 6.16 mmol) at 0° C. The solution was stirred at room temperature for 0.5 h. At 0° C., 1-(6-chloropyridin-3-yl)ethan-1-one (4) (0.9 g, 5.78 mmol) was added and the solution was stirred for 1 h. Water was added to the reaction solution, followed by extraction with EtOAc and subsequent sequential washing with water and saline and then the resulting organic layer was dried over Na2SO4. Silica gel column chromatography provided tert-butyl 4-((5-acetylpyridin-2-yl)oxy)piperidine-1-carboxylate (6) as a white solid. MS m/z321 [M+H]+.
- Tert-butyl (S)-4-((5-(1-aminoethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (7) A 100 mL round-bottom flask was charged with a solution of tert-butyl 4-((5-acetylpyridin-2-yl)oxy)piperidine-1-carboxylate (6) (0.26 g, 0.81 mmol) in NH3/EtOH (13 mL), acetic acid (0.49 g, 8.1 mmol) and NaBH3CN (0.1 g, 1.62 mmol). The resulting solution was stirred at 90° C. for 3 h. The reaction progress was monitored by TLC. The pH was adjusted to 8 with NaOH/H2O (3 mol/L). The resulting solution was extracted with DCM. Combined organic layers were dried over Na2SO4. Silica gel column chromatography provided tert-butyl (S)-4-((5-(1-aminoethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (7) as oil. MS m/z322 [M+H]+.
- Tert-butyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (9) A solution oft tert-butyl 44541-aminoethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (7) (0.26 g, 0.81 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.22 g, 0.89 mmol) in DMSO (5 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate(9) as a solid. MS m/z527[M+H]+.
- (S)-4-isopropyl-3-(2-((1-(6-(piperidin-4-yloxy)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) To a solution of tert-butyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (9) (0.2 g, 0.38 mmol) in EtOAc (2 mL), was added dropwise 4N HCl/EtOAc (6 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 3 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-((1-(6-(piperidin-4-yloxy)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as solid. MS m/z427 [M+H]+.
- (4S)-3-(2-((1-(6-((1-acryloylpiperidin-4-yl)oxy)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO7) To a solution of (S)-4-isopropyl-3-(2-(((S)-1-(6-(piperidin-4-yloxy)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.13 g, 0.3 mmol) in dry acetonitrile (2 mL) was added DIEA (78 mg, 0.36 mmol). The resulting mixture was cooled to −20° C. and then acryloyl chloride (33 mg, 0.36 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-3-(2-((1-(6-((1-acryloylpiperidin-4-yl)oxy)pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one. The pure diastereomer was obtained by prep-TLC. (52 mg, 36%). MS m/z481 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.21-8.14 (m, 1H), 8.13-8.03 (m, 1H), 7.88-7.61 (m, 2H), 7.22 (dd, J=5.6, 3.9 Hz, 1H), 6.93-6.69 (m, 2H), 6.18-6.04 (m, 1H), 5.74-5.59 (m, 1H), 5.24-5.12 (m, 1H), 5.08-5.47 (m, 1H), 4.68-4.48 (m, 1H), 4.40-4.26 (m, 2H), 3.99-3.77 (m, 2H), 3.49-3.39 (m, 1H), 2.02-1.87 (m, 2H), 1.65-1.50 (m, 2H), 1.44 (d, J=6.9 Hz, 3H), 1.31-1.17 (m, 2H), 0.85 (dd, J=68.4, 6.8 Hz, 3H), 0.73-0.44 (m, 3H).
-
- Tert-butyl (1-(4-nitrobenzyl)piperidin-4-yl)carbamate (3) To a solution of tert-butyl piperidin-4-ylcarbamate (1.0 g, 5.0 mmol) in dry dimethyl sulfoxide (30 mL) was added 1-(chloromethyl)-4-nitrobenzene (1.0 g, 5.8 mmol). The mixture was stirred at 90° C. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried, filtered and concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.4 g, 40%). MS m/z 336 [M+H]+.
- 1-(4-nitrobenzyl)piperidin-4-amine (4) To a round-bottom flask containing tert-butyl (1-(4-nitrobenzyl)piperidin-4-yl)carbamate (0.25 g, 0.65 mmol) was added with hydrochloric acid (4N in ethyl acetate, 5 mL). The resulting solution was stirred at room temperature. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and extracted with dichloromethane, concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.2 g, 95%).
- (S)-4-isopropyl-3-(2-((1-(4-nitrobenzyl)piperidin-4-yl)amino)pyrimidin-4-yl)oxazolidin-2-one (6) To a solution of 1-(4-nitrobenzyl)piperidin-4-amine (0.2 g, 0.85 mmol) in dry dimethyl sulfoxide (30 mL) was added (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (0.3 g, 1.2 mmol). The mixture was stirred at 90° C. The reaction mixture was quenched with water and extracted with dichloromethane. The combined extracts were dried and concentrated under reduced pressure. The residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.16 g, 50%). MS m/z 441 [M+H]+.
- (S)-3-(2-((1-(4-aminobenzyl)piperidin-4-yl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (7) To a solution of (S)-4-isopropyl-3-(2-((1-(4-nitrobenzyl)piperidin-4-yl)amino)pyrimidin-4-yl)oxazolidin-2-one (0.16 g, 0.25 mmol) in methanol (10 mL) was added Pd/C (0.2 g). The resulting mixture was stirred at room temperature under H2. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a white solid (0.12 g, 95%). MS m/z411[M+H]+.
- (S)—N-(4-((4-((4-(4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)methyl)phenyl)acrylamide (ISO8) To a solution of (S)-3-(2-((1-(4-aminobenzyl)piperidin-4-yl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (7) (0.12 g, 0.29 mmol) in dichloromethane (5 mL) was added triethylamine (60 mg, 0.45 mmol) and acryloyl chloride (28 mg, 0.33 mmol) at −30° C. The reaction mixture was diluted with water and saturated aqueous sodium bicarbonate. Dichloromethane was added and the organic layer was dried. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a white solid (25 mg, 20%). MS m/z 465[M+H]+. 1H NMR (400 MHz, DMSO) δ 11.31 (s, 1H), 10.83 (s, 1H), 8.18 (d, J=5.4 Hz, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.65-7.52 (m, 2H), 7.24 (d, J=5.2 Hz, 1H), 6.70-6.55 (m, 1H), 6.27 (dd, J=17.0, 1.9 Hz, 1H), 5.75 (dd, J=10.2, 1.9 Hz, 1H), 4.75-4.55 (m, 1H), 4.45-4.30 (m, 2H), 4.30-4.10 (m, 2H), 3.35-3.20 (m, 2H), 3.10-2.80 (m, 2H), 2.45-2.35 (m, 1H), 2.23-1.74 (m, 4H), 0.88 (d, J=9.4 Hz, 3H), 0.76 (d, J=6.8 Hz, 3H).
-
- Tert-butyl (S)-(1-(4-nitrobenzyl)piperidin-3-yl)carbamate (3) To a solution of tert-butyl (S)-piperidin-3-ylcarbamate (1.0 g, 5.0 mmol) in dry dimethyl sulfoxide (30 mL) was added 1-(chloromethyl)-4-nitrobenzene (1.0 g, 5.8 mmol). The mixture was stirred for 1 h at 90° C. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried, filtered and concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.4 g, 40%). MS m/z 336 [M+H]+.
- (S)-1-(4-nitrobenzyl)piperidin-3-amine (4) To a round-bottom flask containing tert-butyl (S)-(1-(4-nitrobenzyl)piperidin-3-yl)carbamate (0.25 g, 0.65 mmol) was added with hydrochloric acid (4N in ethyl acetate, 5 mL). The resulting solution was stirred at room temperature. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and extracted with dichloromethane, concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.2 g, 95%).
- (S)-4-isopropyl-3-(2-(((S)-1-(4-nitrobenzyl)piperidin-3-yl)amino)pyrimidin-4-yl)oxazolidin-2-one (6) To a solution of (S)-1-(4-nitrobenzyl)piperidin-3-amine (0.2 g, 0.85 mmol) in dry dimethyl sulfoxide (30 mL) was added (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (0.3 g, 1.2 mmol). The mixture was stirred at 90° C. The reaction mixture was quenched with water and extracted with dichloromethane. The combined extracts were dried and concentrated under reduced pressure. The residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.16 g, 50%). MS m/z 441 [M+H]+.
- (S)-3-(2-(((S)-1-(4-aminobenzyl)piperidin-3-yl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (7) To a solution of (S)-4-isopropyl-3-(2-(((S)-1-(4-nitrobenzyl)piperidin-3-yl)amino)pyrimidin-4-yl)oxazolidin-2-one (0.16 g, 0.25 mmol) in methanol (10 mL) was added Pd/C (0.2 g). The resulting mixture was stirred at room temperature under H2. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a white solid (0.12 g, 95%). MS m/z 411[M+H]+.
- N-(4-(((S)-3-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)methyl)phenyl)acrylamide (ISO9) To a solution of (S)-3-(2-(((S)-1-(4-aminobenzyl)piperidin-3-yl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (7) (0.12 g, 0.29 mmol) in dichloromethane (5 mL) was added triethylamine (60 mg, 0.45 mmol) and acryloyl chloride (28 mg, 0.33 mmol) at −30° C. The reaction mixture was diluted with water and saturated aqueous sodium bicarbonate. Dichloromethane was added and the organic layer was dried. Concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a white solid (25 mg, 20%). MS m/z 465[M+H]+. 1H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 8.16 (d, J=5.5 Hz, 1H), 7.67 (s, 2H), 7.33 (s, 1H), 7.22 (s, 2H), 7.10-6.90 (m, 1H), 6.60-6.40 (m, 1H), 6.25 (dd, J=17.0, 1.6 Hz, 1H), 5.74 (d, J=10.1 Hz, 1H), 4.75-4.60 (m, 1H), 4.45-4.27 (m, 2H), 3.95-3.65 (m, 1H), 3.59-3.35 (m, 1H), 3.17 (d, J=4.9 Hz, 1H), 3.05-2.75 (m, 1H), 2.75-2.50 (m, 1H), 2.50-2.30 (m, 1H), 2.05-1.79 (m, 2H), 1.79-1.43 (m, 2H), 1.39-1.25 (m, 1H), 1.01-0.80 (m, 3H), 0.74 (d, J=6.9 Hz, 3H).
-
- Tert-butyl (1-(4-nitrobenzyl)pyrrolidin-3-yl)carbamate (3) To a solution of tert-butyl pyrrolidin-3-ylcarbamate (1.0 g, 5.4 mmol) in dry dimethyl sulfoxide (30 mL) was added 1-(chloromethyl)-4-nitrobenzene (1.1 g, 6.1 mmol). The mixture was stirred for 1 h at 90° C. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried, filtered and concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.3 g, 35%). MS m/z 322 [M+H]+.
- 1-(4-nitrobenzyl)pyrrolidin-3-amine (4) To a round-bottom flask containing tert-butyl (1-(4-nitrobenzyl)pyrrolidin-3-yl)carbamate (0.25 g, 0.65 mmol) was added with hydrochloric acid (4N in ethyl acetate, 5 mL). The resulting solution was stirred at room temperature. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and extracted with dichloromethane, concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.2 g, 95%).
- (4S)-4-isopropyl-3-(2-((1-(4-nitrobenzyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)oxazolidin-2-one (6) To a solution of 1-(4-nitrobenzyl)pyrrolidin-3-amine (0.2 g, 0.85 mmol) in dry dimethyl sulfoxide (30 mL) was added (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (0.3 g, 1.2 mmol). The mixture was stirred at 90° C. The reaction mixture was then quenched with water and extracted with dichloromethane. The combined extracts were dried and concentrated under reduced pressure. The residue was purified by silica gel chromatography to afford the compound as a light yellow solid (0.12 g, 40%). MS m/z 427 [M+H]+.
- (4S)-3-(2-((1-(4-aminobenzyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (7) To a solution of (4S)-4-isopropyl-3-(2-((1-(4-nitrobenzyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)oxazolidin-2-one (0.12 g, 0.20 mmol) in methanol (10 mL) was added Pd/C (0.2 g). The resulting mixture was stirred at room temperature under H2. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a white solid (0.09 g, 95%). MS m/z 397[M+H]+.
- N-(4-((3-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)pyrrolidin-1-yl)methyl)phenyl)acrylamide (ISO10) To a solution of (45)-3-(2-((1-(4-aminobenzyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (7) (0.09 g, 0.25 mmol) in dichloromethane (5 mL) was added triethylamine (48 mg, 0.36 mmol) and acryloyl chloride (21 mg, 0.28 mmol) at −30° C. The reaction mixture was diluted with water and saturated aqueous sodium bicarbonate. Dichloromethane was added and the organic layer was dried. Concentrated under reduced pressure and the residue was purified by silica gel chromatography to afford the compound as a white solid (22 mg, 31%). MS m/z 451[M+H]+. 1H NMR (400 MHz, DMSO) δ1H NMR (400 MHz, DMSO) δ 11.60-11.22 (m, 1H), 10.58 (s, 1H), 8.21 (d, J=5.7 Hz, 1H), 7.83-7.65 (m, 2H), 7.51 (d, J=8.8 Hz, 2H), 7.32 (d, J=5.7 Hz, 1H), 6.55-6.42 (m, 1H), 6.29 (dd, J=17.0, 1.8 Hz, 1H), 5.80 (dd, J=10.1, 1.8 Hz, 1H), 4.78-4.60 (m, 2H), 4.55-4.25 (m, 4H), 3.58-3.40 (m, 2H), 3.25-2.93 (m, 2H), 2.20-2.01 (m, 2H), 0.95-0.75 (m, 3H), 0.74 (dd, J=16.9, 6.7 Hz, 3H).
-
- Tert-butyl 4-((5-bromopyrimidin-2-yl)oxy)piperidine-1-carboxylate (3) Tert-butyl 4-hydroxypiperidine-1-carboxylate (2) (2.42 g, 12 mmol) was added to a DMF suspension (10 mL) of 60% sodium hydride (0.8 g, 20 mmol) at 0° C. and the solution was stirred at room temperature for 1 h. 5-bromo-2-chloropyrimidine (1) (1.93 g, 10 mmol) was then added and the solution was stirred for 1 h. Water was added to the reaction solution, followed by extraction with EtOAc and subsequent sequential washing with water and saline and then the resulting organic layer was dried over Na2SO4. Silica gel column chromatography provided tert-butyl 4-((5-bromopyrimidin-2-yl)oxy)piperidine-1-carboxylate (3) as a white solid. MS m/z358 [M+H]+.
- 1-(2-(piperidin-4-yloxy)pyrimidin-5-yl)ethan-1-one (5) PdCl2(PPh3)2 (0.21 g, 0.29 mmol) was added to a solution of tert-butyl 4-((5-bromopyrimidin-2-yl)oxy)piperidine-1-carboxylate (3) (2.11 g, 5.89 mmol) and tributyl(1-ethoxyvinyl)stannane (4) (2.34 g, 6.48 mmol) in THF (30 mL). The solution was degassed and filled with nitrogen twice and then it was heated at 70° C. for 12 h. The reaction mixture was quenched with 2 M KF (20 mL) and extracted with EtOAc. The combined organic layers were washed with 2M KF, brine, dried over Na2SO4, and concentrated under vacuum to afford a yellow residue which was used in the next step without purification.
- The above crude (5.89 mmol) was diluted with MeOH (15 mL) and 1M HCl (5 mL) added. The resulting yellow solution was stirred at room temperature for 2 h, and then the organic solvent was removed under reduced pressure. The residue was diluted with water, the solution was neutralized with 1N NaOH and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4. Silica gel column chromatography provided 1-(2-(piperidin-4-yloxy)pyrimidin-5-yl)ethan-1-one (5). MS m/z222 [M+H]+.
- Tert-butyl 4-((5-acetylpyrimidin-2-yl)oxy)piperidine-1-carboxylate (6) To a solution of 1-(2-(piperidin-4-yloxy)pyrimidin-5-yl)ethan-1-one (5) (0.22 g, 1 mmol) in DCM (5 mL) was added di-tert-butyl dicarbonate (0.26 g, 1.2 mmol) and TEA (0.2 g, 2 mmol). The solution was stirred for 2 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl 4-((5-acetylpyrimidin-2-yl)oxy)piperidine-1-carboxylate (6). MS m/z322 [M+H]+.
- Tert-butyl 4-((5-(1-aminoethyl)pyrimidin-2-yl)oxy)piperidine-1-carboxylate(7) A 100 mL round-bottom flask was charged with a solution of tert-butyl 4-((5-acetylpyrimidin-2-yl)oxy)piperidine-1-carboxylate (6) (1 g, 3.11 mmol) in NH3/EtOH (50 mL), acetic acid (1.87 g, 31.1 mmol) and NaBH3CN (0.39 g, 6.22 mmol). The resulting solution was stirred at 90° C. for 3 h. The reaction progress was monitored by TLC. The pH was adjusted to 8 with NaOH/H2O (3 mol/L). The resulting solution was extracted with DCM. Combined organic layers were dried over Na2SO4. Silica gel column chromatography provided tert-butyl 4-((5-(1-aminoethyl)pyrimidin-2-yl)oxy)piperidine-1-carboxylate (7). MS m/z323 [M+H]+.
- Tert-butyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-2-yl)oxy)piperidine-1-carboxylate (9) A solution of tert-butyl 44541-aminoethyl)pyrimidin-2-yl)oxy)piperidine-1-carboxylate (7) (0.95 g, 3 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.8 g, 3.3 mmol) in DMSO (10 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-2-yl)oxy)piperidine-1-carboxylate (9) as a solid. MS m/z528[M+H]+.
- (4S)-4-isopropyl-3-(2-((1-(2-(piperidin-4-yloxy)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) To a solution of tert-butyl 4-((5-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-2-yl)oxy)piperidine-1-carboxylate (9) (0.4 g, 0.76 mmol) in EtOAc (2 mL), was added 4N HCl/EtOAc (6 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 1 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (4S)-4-isopropyl-3-(2-((1-(2-(piperidin-4-yloxy)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as solid. MS m/z428 [M+H]+.
- (4S)-3-(2-((1-(2-((1-acryloylpiperidin-4-yl)oxy)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO11) To a solution of (45)-4-isopropyl-3-(2-((1-(2-(piperidin-4-yloxy)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.15 g, 0.35 mmol) in dry acetonitrile (2 mL) was added DIEA (90 mg, 0.7 mmol). The resulting mixture was cooled to −20° C. and then acryloyl chloride (38 mg, 0.42 mmol) was added, the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (4S)-3-(2-((1-(2-((l-acryloylpiperidin-4-yl)oxy)pyrimidin-5-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one as a white solid (52 mg, 36%). pure diastereomer was obtained by prep-TLC. MS m/z482 [M+H]+. 1H NMR (400 MHz, DMSO) δ 8.65-8.50 (m, 2H), 8.18 (d, J=5.7 Hz, 1H), 7.81 (s, 1H), 7.25 (dd, J=5.7, 3.3 Hz, 1H), 6.88-6.78 (m, 1H), 6.15-6.02 (m, 1H), 5.67 (dd, J=10.5, 2.4 Hz, 1H), 5.20-5.10 (m, 1H), 5.05-4.95 (m, 1H), 4.66-4.57 (m, 1H), 4.45-4.25 (m, 2H), 3.95-3.75 (m, 2H), 3.50-3.40 (m, 1H), 2.05-1.90 (m, 2H), 1.68-1.58 (m, 2H), 1.48 (d, J=7.0 Hz, 3H), 1.35-1.15 (m, 2H), 0.97-0.72 (m, 3H), 0.56 (s, 3H).
-
- 1-(5-bromopyrimidin-2-yl)ethan-1-ol (2) 5-bromo-2-iodopyrimidine (1) (10 g, 35.1 mmol) was dissolved in THF (150 mL) and methylmagnesium chloride (3 M in Et2O, 24 mL) was added at −78° C., then the mixture was stirred at −78° C. for 1 h. Acetaldehyde (4.64 g, 105.3 mmol) was added dropwise to the solution and the reaction was allowed to stir whilst warming to 0° C. over 1 h. MeOH was then added and the mixture concentrated under reduced pressure. The resultant solid was dissolved in DCM and washed with brine. Silica gel column chromatography provided 1-(5-bromopyrimidin-2-yl)ethan-1-ol (2). MS m/z204 [M+H]+.
- 2-(1-azidoethyl)-5-bromopyrimidine (3) A round-bottom flask containing 1-(5-bromopyrimidin-2-yl)ethan-1-ol (2) (2.92 g, 14.4 mmol) was charged with TEA (1.75 g, 17.3 mmol) and anhydrous DCM (30 mL) at ambient temperature. The resulting mixture was allowed to stir at room temperature for 3 h and the volatile components were removed under reduced pressure. The residue was dissolved in DMF (45 mL) and treated with NaN3 (1.87 g, 28.8 mmol). The resulting mixture was stirred at room temperature for 24 h and was then partitioned between EtOAc and brine. Combined organic layer were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided 2-(1-azidoethyl)-5-bromopyrimidine (3).
- 1-(5-bromopyrimidin-2-yl)ethan-1-amine (4) A mixture of 2-(1-azidoethyl)-5-bromopyrimidine (3) (1.37 g, 6 mmol) and PPh3 (2.04 g, 9 mmol) in MeOH (10 mL). was heated at 80° C. for 3 h. Then it was extracted with EtOAc and organic layers were washed with water and brine, dried (Na2SO4). The mixture is filtered and concentrated. Silica gel column chromatography provided 1-(5-bromopyrimidin-2-yl)ethan-1-amine (4). MS m/z203[M+H]+.
- Tert-butyl (1-(5-bromopyrimidin-2-yl)ethyl)carbamate (5) To a solution of 1-(5-bromopyrimidin-2-yl)ethan-1-amine (4) (1.1 g, 5.4 mmol) in DCM (15 mL) was added di-tert-butyl dicarbonate (1.3 g, 5.94 mmol) and TEA (1.1 g, 10.8 mmol). The solution was stirred for 4 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (1-(5-bromopyrimidin-2-yl)ethyl)carbamate (5).
- Tert-butyl (1-(5-(methyl(4-nitrophenyl)amino)pyrimidin-2-yl)ethyl)carbamate (7) The N-methyl-4-nitroaniline (6) (0.85 g, 3.1 mmol), X-Phos (0.14 g), Pd2(dba)3 (55 mg) and anhydrous K2CO3 (0.77 g, 5.6 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and filled with nitrogen. A solution of tert-butyl (1-(5-bromopyrimidin-2-yl)ethyl)carbamate (5) (0.85 g, 2.8 mmol) in toluene (12 ml), were added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. And a saturated solution of NaCl was added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (1-(5-(methyl(4-nitrophenyl)amino)pyrimidin-2-yl)ethyl)carbamate (7). MS m/z374[M+H]+.
- 2-(1-aminoethyl)-N-methyl-N-(4-nitrophenyl)pyrimidin-5-amine (8) To a solution of tert-butyl (1-(5-(methyl(4-nitrophenyl)amino)pyrimidin-2-yl)ethyl)carbamate (7) (0.45 g, 1.2 mmol) in EtOAc (2 mL) was added 4N HCl/EtOAc (8 mL) in an ice bath. The resulting mixture was stirred at room temperature for 1.5 h and saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided 2-(1-aminoethyl)-N-methyl-N-(4-nitrophenyl)pyrimidin-5-amine (8).
- (4S)-4-isopropyl-3-(2-((1-(5-(methyl(4-nitrophenyl)amino)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) A solution of 2-(1-aminoethyl)-N-methyl-N-(4-nitrophenyl)pyrimidin-5-amine (8) (0.25 g, 0.9 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (9) (0.22 g, 0.9 mmol) in DMSO (5 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (4S)-4-isopropyl-3-(2-((1-(5-(methyl(4-nitrophenyl)amino)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as a solid. MS m/z479 [M+H]+.
- (4S)-3-(2-((1-(5-((4-aminophenyl)(methyl)amino)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (11) A mixture of (4S)-4-isopropyl-3-(2-((1-(5-(methyl(4-nitrophenyl)amino)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.2 g, 0.4 mmol) and 10% Pd—C(0.1 g) in MeOH (5 mL) is stirred under hydrogen for 2 h. The mixture is filtered and concentrated. Silica gel column chromatography provided (45)-3-(2-((1-(5-((4-aminophenyl) (methyl)amino)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (11). MS m/z449 [M+H]+.
- N-(4-((2-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-5-yl)(methyl)amino)phenyl)acrylamide (ISO12) To a solution of (4S)-3-(2-((1-(5-((4-aminophenyl)(methyl)amino)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (11) (0.12 g, 0.27 mmol) in dry acetonitrile (2 mL) was added DIEA (70 mg, 0.54 mmol). The resulting mixture was cooled down to −20° C., and then was added with acryloyl chloride (24 mg, 0.27 mmol). The solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided N-(4-((2-(1-((4-4S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-5-yl)(methyl)amino)phenyl)acrylamide as a solid (30 mg, 22%). Pure diastereomer was obtained by prep-TLC. MS m/z503[M+H]+. 1H NMR (400 MHz, DMSO) δ 10.32 (s, 1H), 8.29 (d, J=5.1 Hz, 2H), 8.19-8.11 (m, 1H), 7.71 (d, J=8.5 Hz, 2H), 7.56-7.31 (m, 1H), 7.21 (d, J=5.4 Hz, 1H), 7.18-7.05 (m, 2H), 6.56-6.42 (m, 1H), 6.29-6.20 (m, 1H), 5.74 (dd, J=10.1, 1.6 Hz, 1H), 5.01-4.89 (m, 1H), 4.70-4.17 (m, 3H), 3.27 (d, J=4.3 Hz, 3H), 2.58-2.51 (m, 1H), 1.47 (t, J=7.2 Hz, 3H), 0.96-0.72 (m, 3H), 0.71-0.48 (m, 3H).
-
- 1-(5-bromopyrimidin-2-yl)ethan-1-ol (2) 5-bromo-2-iodopyrimidine (1) (10 g, 35.1 mmol) was dissolved in THF (150 mL) and methyl magnesium chloride (3 M in Et2O, 24 mL) was added at −78° C., then the mixture was stirred at −78° C. for 1 h. Acetaldehyde (4.64 g, 105.3 mmol) was added dropwise to the resulting solution and the reaction was allowed to stir whilst warming to 0° C. over 1 h. MeOH was added and the mixture concentrated in vacuo. The resultant solid was dissolved in DCM and washed with brine. Silica gel column chromatography provided 1-(5-bromopyrimidin-2-yl)ethan-1-ol (2). MS m/z204 [M+H]+.
- 2-(1-azidoethyl)-5-bromopyrimidine (3) A round-bottom flask containing 1-(5-bromopyrimidin-2-yl)ethan-1-ol (2) (2.92 g, 14.4 mmol) was charged with TEA (1.75 g, 17.3 mmol) and DCM (30 mL) at room temperature. The resulting mixture was allowed to stir at room temperature for 3 h and the volatile components were removed under reduced pressure. The residue was dissolved in DMF (45 mL) and treated with NaN3 (1.87 g, 28.8 mmol). The resulting mixture was stirred at room temperature for 24 h and was then partitioned between EtOAc and brine. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided 2-(1-azidoethyl)-5-bromopyrimidine (3).
- 1-(5-bromopyrimidin-2-yl)ethan-1-amine (4) A mixture of 2-(1-azidoethyl)-5-bromopyrimidine (3) (1.37 g, 6 mmol) and PPh3 (2.04 g, 9 mmol) in MeOH (10 mL). The resulting mixture was heated at 80° C. for 3 h. Then it was extracted with EtOAc and organic layers were washed with water and brine, dried (Na2SO4). The mixture is filtered and concentrated. Silica gel column chromatography provided 1-(5-bromopyrimidin-2-yl)ethan-1-amine (4). MS m/z203[M+H]+.
- Tert-butyl (1-(5-bromopyrimidin-2-yl)ethyl)carbamate (5) To a solution of 1-(5-bromopyrimidin-2-yl)ethan-1-amine (4) (1.1 g, 5.4 mmol) in DCM (15 mL) was added di-tert-butyl dicarbonate (1.3 g, 5.94 mmol) and TEA (1.1 g, 10.8 mmol). The solution was stirred for 4 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (1-(5-bromopyrimidin-2-yl)ethyl)carbamate (5).
- Tert-butyl (1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethyl)carbamate(7) The (3-nitrophenyl)boronic acid (6) (0.62 g, 3.72 mmol), Pd(PPh3)4 (0.1 g) and anhydrous K2CO3 (0.69 g, 4.96 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and filled with nitrogen. A solution of tert-butyl (1-(5-bromopyrimidin-2-yl)ethyl)carbamate (5) (0.75 g, 2.48 mmol) in THF (12 mL) and H2O (5 mL) was added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled down to room temperature. Then a saturated solution of NaCl was added and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethyl)carbamate (7). MS m/z345[M+H]+.
- 1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethan-1-amine (8) To a solution of tert-butyl (1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethyl)carbamate (7) (0.55 g, 1.6 mmol) in EtOAc (2 mL) was added 4N HCl/EtOAc (10 mL) in an ice bath. The resulting mixture was stirred at room temperature for 1.5 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided 1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethan-1-amine (8).
- (4S)-4-isopropyl-3-(2-((1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) A solution of 1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethan-1-amine (8) (0.4 g, 1.6 mmol) and (S)-3-(2-chloropyrimidin-4-yl)-4-isopropyloxazolidin-2-one (9) (0.46 g, 1.92 mmol) in DMSO (5 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (4S)-4-isopropyl-3-(2-((1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) as a solid. MS m/z450 [M+H]+.
- (4S)-3-(2-((1-(5-(3-aminophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (11) A mixture of (45)-4-isopropyl-3-(2-((1-(5-(3-nitrophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (10) (0.3 g, 0.67 mmol) and 10% Pd—C(0.1 g) in MeOH (5 mL) is stirred under hydrogen for 2 h. The mixture is filtered and concentrated. Silica gel column chromatography provided (4S)-3-(2-((1-(5-(3-aminophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (11). MS m/z420 [M+H]+.
- N-(3-(2-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-5-yl)phenyl)acrylamide (ISO13) To a solution of (4S)-3-(2-((1-(5-(3-aminophenyl)pyrimidin-2-yl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (11) (0.12 g, 0.29 mmol) in dry acetonitrile (2 mL) was added DIEA (75 mg, 0.58 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (31 mg, 0.34 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided N-(3-(2-(1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)pyrimidin-5-yl)phenyl)acrylamide (ISO13) as a solid (30 mg, 22%). Pure diastereomer was obtained by prep-TLC. MS m/z474[M+H]+. 1H NMR (400 MHz, DMSO) δ 10.46 (d, J=4.0 Hz, 1H), 9.00 (s, 1H), 8.88 (s, 1H), 8.24-8.10 (m, 1H), 8.05 (s, 1H), 7.80-7.72 (m, 1H), 7.71-7.61 (m, 1H), 7.51-7.39 (m, 2H), 7.25-7.18 (m, 1H), 6.57-6.45 (m, 1H), 6.34-6.28 (m, 1H), 5.82-5.74 (m, 1H), 5.20-4.91 (m, 1H), 4.55-4.11 (m, 3H), 2.62-2.53 (m, 1H), 1.62-1.50 (m, 3H), 0.99-0.72 (m, 3H), 0.61-0.31 (m, 3H).
-
- Methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) To a solution of methyl (S)-4-(1-aminoethyl)benzoate (1) (4.9 g, 22.7 mmol) in dichloromethane (120 mL) was added di-tert-butyl dicarbonate (5.95 g, 27.3 mmol) and TEA (6.97 ml, 50 mmol). The solution was stirred for 7 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography (EtOAc/
PE 0 to 30%) provided methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) as a white solid (6.2 g, 97.6%). - Tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) To a cooled (0° C.) solution of methyl (S)-4-(1-((tert-butoxycarbonyl)amino)ethyl)benzoate (2) (7.89 g, 28.2 mmol) in THF (142 mL) was added a solution of LiAlH4 (1.3 g, 33.84 mmol) in THF (17 mL) and the resulting mixture was stirred at room temperature for 30 min. The reaction mixture was quenched by addition of a 1N NaOH solution until gas evolution ceased. The reaction mixture was filtered, washed with EtOAc. After separation, the aqueous phase was extracted with EtOAc. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography (EtOAc/
PE 0 to 30%) provided tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) as a white solid (5.6 g, 79%). MS m/z178.08 [M−74+H]+. - Tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) To a solution of tert-butyl (S)-(1-(4-(hydroxymethyl)phenyl)ethyl)carbamate (3) (2.5 g, 10 mmol) in dichloromethane (50 mL) was added methanesulfonyl chloride (1.4 g, 12 mmol) and TEA (2.02 g, 20 mmol). The solution was stirred for 12 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography (EtOAc/
PE 0 to 20%) provided tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) as a white solid (1.28 g, 47.4%). MS m/z196.1 [M−74+H]+. - Benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) To a solution of tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate (4) (1.28 g, 4.74 mmol) in DMF (6 mL) was added benzyl piperazine-1-carboxylate(1.15 g, 5.22 mmol) and K2CO3 (1.97 g, 14.22 mmol). The resulting mixture was heated at 80° C. for 3 h. Then it was extracted with EtOAc and organic layers were washed with water and brine, dried, and concentrated. Silica gel column chromatography provided benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) as a white solid (0.92 g, 42.8%). MS m/z454.26 [M+H]+.
- Benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) To a solution of benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate (6) (0.45 g, 1 mmol) in EtOAc (3 mL), was added 4N HCl/EtOAc (8 mL) in an ice bath. The resulting mixture was stirred at room temperature for 3 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then the solution was extracted with EtOAc. Organic layers were dried, and concentrated. Silica gel column chromatography (EtOAc/
PE 0 to 50%) provided benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) as a white solid (0.34 g, 97%). MS m/z354.21 [M+H]+. - (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A solution of (S)-4-isopropyloxazolidin-2-one (A) (1.3 g, 10 mmol) and 2,4-dichlorothieno[3,2-d]pyrimidine (B) (2 g, 10 mmol) in 10 mL DMF was cooled to 0° C. under N2. NaH (0.52 g of 60% suspension, 13 mmol) was slowly added to the solution and the temperature was kept below 5° C. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 3 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organics were dried, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) as a white solid. MS m/z298.1 [M+H]+.
- Benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate (9) A solution of benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate (7) (0.35 g, 1 mmol) and (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.3 g, 1 mmol) in DMSO (5 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate (9) as a white solid. MS m/z615.21 [M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)thieno [3,2-]pyrimidin-4-yl)oxazolidin-2-one (10) A mixture of benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl) benzyl)piperazine-1-carboxylate (9) (0.61 g, 1 mmol) and 10% Pd—C(0.61 g) in ethanol (5 mL) is stirred under hydrogen for overnight. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (10). MS m/z481.23 [M+H]+.
- (S)-3-(2-(((S)-1-(4-((4-acryloylpiperazin-1-yl)methyl)phenyl)ethyl)amino)thieno [3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO14) To a solution of (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (10) (39 mg, 0.081 mmol) in dry acetonitrile (1 mL) was added DIEA (21 mg, 0.162 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (15 mg, 0.612 mmol) was added and resulting solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried, and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((4-acryloylpiperazin-1-yl)methyl)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO14) as a white solid. MS m/z535.21 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.15 (d, J=5.6 Hz, 1H), 7.71 (br, 1H), 7.33 (d, J=7.7 Hz, 2H), 7.21 (d, J=7.7 Hz, 2H), 7.10 (d, J=5.6 Hz, 1H), 6.76 (m, 10.4, 4.2 Hz, 1H), 6.08 (m, 2.7 Hz, 1H), 5.65 (m, 1H), 5.08 (s, 1H), 4.80 (s, 1H), 4.52 (m, 1H), 4.33 (m, 1H), 3.46-3.56 (m, 4H), 3.42 (s, 2H), 3.41-3.37 (m, 1H), 2.30 (s, 4H), 1.44 (d, J=7.0 Hz, 3H), 0.48 (m, 6H).
-
- (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) To a solution of (S)-1-(4-bromophenyl)ethan-1-amine (1) (2 g, 10 mmol) in DCM (20 mL) was added di-tert-butyl dicarbonate (2.4 g, 11 mmol) and TEA (1.27 g, 12.4 mmol). The solution was stirred for 3 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) as a white solid (2.9 g, 96.7%).
- Tert-butyl (S)-(1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)carbamate (4) The 5-nitropyridin-2-amine (3) (1.38 g, 9.9 mmol), CuI (0.95 g, 5 mmol) and K2CO3 (2.49 g. 18 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and filled with nitrogen gas three times. A solution of (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) (2.69 g, 9 mmol) and DMEDA (0.44 g, 5 mmol) in dioxane (45 mL), were added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. And a saturated solution of NaCl was added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (S)-(1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)carbamate (4) as a yellow solid.
- (S)—N-(4-(1-aminoethyl)phenyl)-5-nitropyridin-2-amine (5) To a solution of Tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate (4) (1.2 g, 3.35 mmol) in EtOAc, was added 4N HCl/EtOAc (10 mL) in an ice bath. The resulting mixture was stirred at room temperature for 3 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)—N-(4-(1-aminoethyl)phenyl)-5-nitropyridin-2-amine (5) as a yellow solid.
- (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichlorothieno[3,2-d]pyrimidine (b) (8.4 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) as a white solid. MS m/z298 [M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (7) A solution of (S)—N-(4-(1-aminoethyl)phenyl)-5-nitropyridin-2-amine (5) (0.46 g, 1.55 mmol) and (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) (0.4 g, 1.55 mmol) in DMSO (10 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (7) as a yellow solid. MS m/z520[M+H]+.
- (S)-3-(2-(((S)-1-(4-((5-aminopyridin-2-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A mixture of (S)-4-isopropyl-3-(2-(((S)-1-(4-((5-nitropyridin-2-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (7) (0.27 g, 0.52 mmol) and 10% Pd—C(0.1 g) in MeOH (5 mL) is stirred under hydrogen for 2 h. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((5-aminopyridin-2-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8). MS m/z490 [M+H]+.
- N-(6-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)pyridin-3-yl)acrylamide (ISO17) To a solution of (S)-3-(2-(((S)-1-(4-((5-aminopyridin-2-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (0.14 g, 0.286 mmol) in dry acetonitrile (3 mL) was added DIEA (74 mg, 0.572 mmol). The resulting mixture was cooled down to −20° C., and then adding acryloyl chloride (26 mg, 0.286 mmol), stirring for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided N-(6-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)pyridin-3-yl)acrylamide (ISO17) as a solid (54 mg, 35%). MS m/z544[M+H]+. 1H NMR (400 MHz, DMSO) δ 10.03 (s, 1H), 8.86 (s, 1H), 8.36 (d, J=2.5 Hz, 1H), 8.13 (d, J=5.5 Hz, 1H), 7.82 (dd, J=8.9, 2.6 Hz, 1H), 7.70-7.53 (m, 1H), 7.53-7.44 (m, 2H), 7.30-7.20 (m, 2H), 7.10 (d, J=5.6 Hz, 1H), 6.78 (d, J=8.9 Hz, 1H), 6.45-6.35 (m, 1H), 6.26-6.17 (m, 1H), 5.79-5.65 (m, 1H), 5.15-4.75 (m, 2H), 4.53 (t, J=8.9 Hz, 1H), 4.40-4.27 (m, 1H), 2.57-2.51 (m, 1H), 1.45 (d, J=7.0 Hz, 3H), 0.87-0.42 (m, 6H).
-
- (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) To a solution of (S)-1-(4-bromophenyl)ethan-1-amine (1) (2 g, 10 mmol) in DCM (20 mL) was added di-tert-butyl dicarbonate (2.4 g, 11 mmol) and TEA (1.27 g, 12.4 mmol). The solution was stirred for 3 h at room temperature then washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) as a white solid (2.9 g, 96.7%).
- Tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate (4) The 4-nitroaniline (3) (1.01 g, 7.34 mmol), CuI (1.27 g, 6.67 mmol) and anhydrous K2CO3 (1.84 g. 13.34 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and filled with nitrogen. A solution of (S)-2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)ethan-1-ylium (2) (2 g, 6.67 mmol) and DMEDA (0.59 g, 6.67 mmol) in 1,4-dioxane (30 mL) were added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. And a saturated solution of NaCl were added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate(4) as a yellow solid.
- (S)-4-(1-aminoethyl)-N-(4-nitrophenyl)aniline (5) To a solution of tert-butyl (S)-(1-(4-((4-nitrophenyl)amino)phenyl)ethyl)carbamate (4) (1.2 g, 3.36 mmol) in EtOAc, was added 4N HCl/EtOAc (10 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 3 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc and organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-4-(1-aminoethyl)-N-(4-nitrophenyl)aniline (5) as a yellow solid.
- (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichlorothieno[3,2-d]pyrimidine (b) (8.4 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2 atmosphere. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) as a white solid. MS m/z298 [M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-((4-nitrophenyl)amino)phenyl)ethyl)amino)thieno[3,2-41] pyrimidin-4-yl)oxazolidin-2-one (7) A solution of (S)-4-(1-aminoethyl)-N-(4-nitrophenyl)aniline (5) (0.4 g, 1.55 mmol) and (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (6) (0.46 g, 1.55 mmol) in DMSO (10 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-((4-nitrophenyl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (7) as a yellow solid. MS m/z519[M+H]+.
- (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) A mixture of (S)-4-isopropyl-3-(2-(((S)-1-(4-((4-nitrophenyl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (7) (0.26 g, 0.5 mmol) and 10% Pd—C(0.1 g) in MeOH (5 mL) is stirred under hydrogen for 2 h. The mixture is filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8). MS m/z489 [M+H]+.
- N-(4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)acrylamide (ISO18) To a solution of (S)-3-(2-(((S)-1-(4-((4-aminophenyl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (8) (70 mg, 0.14 mmol) in dry acetonitrile (1 mL) was added DIEA (36 mg, 0.28 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (13 mg, 0.14 mmol) was added and the resulted solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided N-(4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)phenyl)acrylamide (ISO18) as a solid (30 mg, 39%). MS m/z543[M+H]+.
-
- (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (2) A solution of (S)-4-isopropyloxazolidin-2-one (a) (5.3 g, 41 mmol) and 2,4-dichlorothieno[3,2-d]pyrimidine (b) (8.4 g, 41 mmol) in 30 mL DMF was cooled to 0° C. under N2. NaH (2.1 g of 60% suspension, 53 mmol) was slowly added. After 5 min, cold bath was removed. Reaction mixture was allowed to warm to room temperature and stirred 12 h. The reaction mixture was diluted with water and extracted with EtOAc. Organic layer was washed water, and brine. Combined organic layers were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (2) as a white solid. MS m/z298 [M+H]+.
- (S)-3-(2-(((S)-1-(4-bromophenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) A solution of (S)-1-(4-bromophenyl)ethan-1-amine (1) (4 g, 20 mmol) and (S)-3-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (2) (6.5 g, 22 mmol) in DMSO (10 mL) was heated at 110° C. for 3 h. The reaction mixture was extracted with EtOAc and organic layers were washed with water. After separation, the aqueous phase was extracted with EtOAc. Combined organics were dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-bromophenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) as a solid. MS m/z462 [M+H]+.
- Tert-butyl 4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)piperidine-1-carboxylate (5) The tert-butyl 4-aminopiperidine-1-carboxylate (4) (0.23 g, 1.14 mmol), X-Phos (30 mg), Pd2(dba)3 (15 mg) and anhydrous K2CO3 (0.26 g, 1.9 mmol) were added to a Schlenk-type, three-neck flask fitted with a thermometer, magnetic stirrer bar and septum. The flask was evacuated and filled with nitrogen. A solution of (S)-3-(2-(((S)-1-(4-bromophenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (3) (0.44 g, 0.95 mmol) in 1,4-dioxane (12 mL), was added by syringe at room temperature. The reaction mixture was stirred at 100° C. for 12 h and then cooled to room temperature. And a saturated solution of NaCl was added, and the mixture was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated. Silica gel column chromatography provided tert-butyl 4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)piperidine-1-carboxylate (5). MS m/z581 [M+H]+.
- (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperidin-4-ylamino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (6) To a solution of tert-butyl 4-((4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)thieno[3,2-d]pyrimidin-2-yl)amino)ethyl)phenyl)amino)piperidine-1-carboxylate (5) (0.29 g, 0.5 mmol) in EtOAc (2 mL), was added 4N HCl/EtOAc (8 mL) in an ice bath. And the resulting mixture was stirred at room temperature for 1 h. And saturated sodium bicarbonate solution was added dropwise, the pH was adjusted to 8-9, then was extracted with EtOAc. The organic layers were dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperidin-4-ylamino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (6) as a solid. MS m/z481 [M+H]+.
- (S)-3-(2-(((S)-1-(4-((1-acryloylpiperidin-4-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO19) To a solution of (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperidin-4-ylamino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxazolidin-2-one (6) (0.1 g, 0.21 mmol) in dry acetonitrile (2 mL) was added DIEA (81.4 mg, 0.63 mmol). The resulting mixture was cooled down to −20° C., and then acryloyl chloride (19.3 mg, 0.21 mmol) was added and the solution was stirred for 5 min. Then it was extracted with DCM and organic layers were washed with water and brine, dried (Na2SO4), and concentrated. Silica gel column chromatography provided (S)-3-(2-(((S)-1-(4-((1-acryloylpiperidin-4-yl)amino)phenyl)ethyl)amino)thieno[3,2-d]pyrimidin-4-yl)-4-isopropyloxazolidin-2-one (ISO19) as a solid. MS m/z535 [M+H]+.
-
TABLE 1 IC50 (M) of Exemplary Compounds Compound ID: IDH1 (R132H) IDH1 (R132C) IDH1 IS01 1.32E-09 1.61E-09 9.46E-06 IS03 3.61E-09 3.35E-09 8.52E-06 IS04 1.05E-08 7.55E-09 >1.00E-05 IS05 4.67E-09 >1.48E-06 IS07 3.40E-07 NA NA IS012 1.61E-07 1.98E-07 NA IS013 1.07E-07 2.85E-07 NA IS014 8.09E-1O 2.61 E-09 NA - Compounds were tested against 3 enzymes WT IDH1, IDH1 R132C, IDH1 R132H
- Assay Format: The production or depletion of NADPH by IDH enzymes was measured by diaphorase/resazurin coupled detection.
- 1. Deliver enzyme/NADP in the reaction buffer into wells of reaction plate except No Enzyme control wells. Add buffer+NADP into No Enzyme wells.
2. Deliver compound in 100% DMSO into the enzyme mixture. Spin down and preincubate for 60 min at room temperature.
3. Deliver Substrate mixture to initiate the reaction. Spin down plate and gently shake 45 minutes at room temperature. - Detection Step for Wt:
- 4. Make a 3× mix of Detection mixture in the reaction buffer, and add detection mixture into the reaction. Spin down.
5. Incubate at room temperature for 10 minutes. - 7. Subtract background (the average value of the No Enzyme control wells) from raw data. Average the DMSO control wells and set value as 100%. Take ratio of measured data/average DMSO
control value times 100% to arrive at % activity. - Reaction Procedure Mutant:
- 8. Deliver enzyme/NADPH in the reaction buffer into wells of reaction plate except No Enzyme control wells. Add buffer+NADPH into No Enzyme wells.
9. Deliver compound in 100% DMSO into the enzyme mixture. Spin down and preincubate for 60 min at room temperature.
10. Deliver Substrate mixture to initiate the reaction. Spin down plate and gently shake 45 minutes at room temperature. - Detection Step (the Same as Wt):
- 11. Make a 3× mix of Detection mixture in the reaction buffer, and add detection mixture into the reaction. Spin down.
12. Incubate at room temperature for 10 minutes. - 14. Subtract raw data from background (the average value of the No Enzyme wells).
Average the DMSO control wells and set value as 100%. Take ratio of measured data/average DMSOcontrol value times 100% to arrive at % activity. - Analyses were performed on a Shimadzu Biotech Axima TOF2 (Shimadzu Instruments) matrix-assisted-laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer. Proteins were analyzed in positive ion linear mode. For intact protein mass measurement the instrument was set with a mass range extending up to 75000 m/z using a pulsed extraction setting of 47000 and apomyoglobin as the standard to calibrate the instrument. A 3 ul aliquot of each sample was diluted with 7 ul of 0.1% TFA prior to micro C4 Zip Tip desalting and deposition directly onto the MALDI target using Sinapinic acid as the desorption matrix (10 mg/mL in 0.1% TFA:Acetonitrile 50:50).
- Applicant's disclosure is described herein in preferred embodiments with reference to the Figures, in which like numbers represent the same or similar elements. Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
- The described features, structures, or characteristics of Applicant's disclosure may be combined in any suitable manner in one or more embodiments. In the description, herein, numerous specific details are recited to provide a thorough understanding of embodiments of the invention. One skilled in the relevant art will recognize, however, that Applicant's composition and/or method may be practiced without one or more of the specific details, or with other methods, components, materials, and so forth. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the disclosure.
- In this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural reference, unless the context clearly dictates otherwise.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Methods recited herein may be carried out in any order that is logically possible, in addition to a particular order disclosed.
- References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made in this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material explicitly set forth herein is only incorporated to the extent that no conflict arises between that incorporated material and the present disclosure material. In the event of a conflict, the conflict is to be resolved in favor of the present disclosure as the preferred disclosure.
- The representative examples are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples and the references to the scientific and patent literature included herein. The examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
Claims (10)
1-36. (canceled)
37. A method for treating, reducing, or preventing a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (I):
wherein,
each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
RE is a group comprising an electrophilic warhead,
or a pharmaceutically acceptable form thereof, or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
38. A method for treating, reducing, or preventing a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula of (II):
wherein,
each of RA and RB is independently H or a halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
Z1 and Z2 is independently CH or N;
R1 is H or a halogen atom; and
R2 is a functional group that comprises an electrophilic group,
or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
39. A method for treating, reducing, or preventing a disease or disorder, comprising administering to a subject in need thereof a pharmaceutical composition comprising a compound having the structural formula (III):
wherein,
each of RA and RB is independently H or halogen, CN, CF3, alkylamine, alkoxy and alky group, or RA and RB join together to form a 5-membered aromatic ring along with the two carbons (—C═C—) of the pyrimidine ring that RA and RB are bonded to respectively;
Z1 and Z2 is independently CH or N;
R1 is H or a halogen atom; and
R2 is a functional group that comprises an electrophilic group,
or a pharmaceutically acceptable form thereof, in an amount effective to treat, prevent, or reduce one or more cancers, or a related disease or disorder thereof, in a mammal, including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.
40. The method of claim 37 , wherein the one or more cancers comprise a blood cancer or a hematologic malignance.
41. The method of claim 40 , wherein the one or more cancers are selected from B-acute lymphoblastic leukemias, B-acute lymphoblastic leukemias, chronic myelomonocytic leukemia, cute myelogenous leukemia, lymphoma, myelodysplasia syndrome, myeloproliferative neoplasms and myeloproliferative neoplasms.
42. The method of claim 38 , wherein the one or more cancers comprise a blood cancer or a hematologic malignance.
43. The method of claim 42 , wherein the one or more cancers are selected from B-acute lymphoblastic leukemias, B-acute lymphoblastic leukemias, chronic myelomonocytic leukemia, cute myelogenous leukemia, lymphoma, myelodysplasia syndrome, myeloproliferative neoplasms and myeloproliferative neoplasms.
44. The method of claim 39 , wherein the one or more cancers comprise a blood cancer or a hematologic malignance.
45. The method of claim 44 , wherein the one or more cancers are selected from B-acute lymphoblastic leukemias, B-acute lymphoblastic leukemias, chronic myelomonocytic leukemia, cute myelogenous leukemia, lymphoma, myelodysplasia syndrome, myeloproliferative neoplasms and myeloproliferative neoplasms.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/472,646 US20210403460A1 (en) | 2016-12-19 | 2021-09-12 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662436328P | 2016-12-19 | 2016-12-19 | |
US201762536367P | 2017-07-24 | 2017-07-24 | |
PCT/US2017/067050 WO2018118793A1 (en) | 2016-12-19 | 2017-12-18 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
US201916467978A | 2019-06-09 | 2019-06-09 | |
US17/472,646 US20210403460A1 (en) | 2016-12-19 | 2021-09-12 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/067050 Division WO2018118793A1 (en) | 2016-12-19 | 2017-12-18 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
US16/467,978 Division US11149032B2 (en) | 2016-12-19 | 2017-12-18 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210403460A1 true US20210403460A1 (en) | 2021-12-30 |
Family
ID=62627122
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,978 Active US11149032B2 (en) | 2016-12-19 | 2017-12-18 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
US17/472,646 Abandoned US20210403460A1 (en) | 2016-12-19 | 2021-09-12 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/467,978 Active US11149032B2 (en) | 2016-12-19 | 2017-12-18 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US11149032B2 (en) |
EP (1) | EP3555079A4 (en) |
JP (1) | JP2020502116A (en) |
KR (1) | KR20190092476A (en) |
CN (1) | CN110291085B (en) |
AU (1) | AU2017379796B2 (en) |
CA (1) | CA3047136A1 (en) |
WO (1) | WO2018118793A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6682043B2 (en) * | 2016-06-06 | 2020-04-15 | イーライ リリー アンド カンパニー | Mutant IDH1 inhibitor |
WO2019213403A1 (en) | 2018-05-02 | 2019-11-07 | Kinnate Biopharma Inc. | Inhibitors of cyclin-dependent kinases |
BR112020026748A2 (en) * | 2018-06-29 | 2021-03-30 | Kinnate Biopharma Inc. | CYCLINE DEPENDENT KINASE INHIBITORS |
CN111825666B (en) * | 2019-04-23 | 2024-03-08 | 上海仕谱生物科技有限公司 | Dimeric or multimeric forms of mutant IDH inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
WO2008080937A1 (en) * | 2006-12-28 | 2008-07-10 | Basf Se | 2-substituted pyrimidines i in therapy |
PE20141581A1 (en) * | 2011-09-27 | 2014-11-14 | Novartis Ag | 3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF MUTANT HDI |
WO2016044781A1 (en) * | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
WO2017140758A1 (en) * | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
JP6682043B2 (en) * | 2016-06-06 | 2020-04-15 | イーライ リリー アンド カンパニー | Mutant IDH1 inhibitor |
-
2017
- 2017-12-18 WO PCT/US2017/067050 patent/WO2018118793A1/en active Application Filing
- 2017-12-18 CA CA3047136A patent/CA3047136A1/en active Pending
- 2017-12-18 AU AU2017379796A patent/AU2017379796B2/en not_active Ceased
- 2017-12-18 CN CN201780086231.0A patent/CN110291085B/en active Active
- 2017-12-18 EP EP17882734.1A patent/EP3555079A4/en not_active Withdrawn
- 2017-12-18 US US16/467,978 patent/US11149032B2/en active Active
- 2017-12-18 JP JP2019531713A patent/JP2020502116A/en active Pending
- 2017-12-18 KR KR1020197019050A patent/KR20190092476A/en unknown
-
2021
- 2021-09-12 US US17/472,646 patent/US20210403460A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2020502116A (en) | 2020-01-23 |
EP3555079A4 (en) | 2020-08-19 |
US11149032B2 (en) | 2021-10-19 |
CN110291085A (en) | 2019-09-27 |
CN110291085B (en) | 2023-01-24 |
EP3555079A1 (en) | 2019-10-23 |
CA3047136A1 (en) | 2018-06-28 |
WO2018118793A1 (en) | 2018-06-28 |
KR20190092476A (en) | 2019-08-07 |
US20200071309A1 (en) | 2020-03-05 |
AU2017379796A1 (en) | 2019-07-04 |
AU2017379796B2 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210403460A1 (en) | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | |
WO2022105855A1 (en) | Kras g12d inhibitors | |
CN115315427B (en) | HPK1 inhibitor and preparation method and application thereof | |
US20210101899A1 (en) | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | |
BR112021011147A2 (en) | PYRAZOLYL-AMINO-PYRIMIDINIL DERIVATIVES BENZAMIDES AND COMPOSITIONS AND METHODS THEREOF | |
CN115073469B (en) | Preparation and application of pyrrolopyrimidine compound as kinase inhibitor | |
US11236083B2 (en) | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | |
US20240083882A1 (en) | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
WO2020215998A1 (en) | Pyrimido five-membered heterocyclic compound and use thereof as mutant idh2 inhibitor | |
CN111051309A (en) | Triazolotriazine derivatives useful as A2A receptor antagonists | |
CN115028633B (en) | Preparation and application of pyrrolopyrimidine compound | |
US20200140444A1 (en) | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | |
WO2022228511A1 (en) | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof | |
KR20230146607A (en) | Pyrimidine compounds as WEE-1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |